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Summary 
Coronary heart disease (CHD) is a serious, chronic and potentially fatal condition, which has consequences 
at multiple levels. For the individual who experiences a CHD event, consequences in the short term include 
changes in mental health, in social life and in lifestyle. In the longer term, the individual’s labour market 
affiliation may be affected, as well as their earnings and consumption. As consequence of the disease, heart 
patients may often change lifestyle and thereby reduce the negative impact of the disease, and in the long 
term reduce the morbidity of CHD and other diseases.  
 
At the health care sector level and at the societal level CHD also has an important impact. Aside from being 
the most frequent cause of hospital admission, CHD also causes changes at societal level, such as changes 
in patients’ labour market affiliation and future earnings and consumption. 
 
The main focus of this assessment of the short and long-term consequences of coronary heart disease is 
the economic evaluation of health care and health promotion interventions. Economic evaluations are 
frequently based on data derived from randomised controlled trials which often apply a rather short study 
time frame. In this thesis I argue that the time perspective of economic evaluations should be long enough 
to be able to capture all relevant costs and effects. I also argue in favour of including other types of data 
sources than those available from RCT-based data: such as long-term data from clinical and administrative 
registers.  
 
This thesis is based on four studies: paper 1 considers the health care costs of CHD and possible impacts of 
lifestyle interventions that may prevent CHD. We found that CHD is associated with a statistically significant 
increase in health care costs and that amongst people at risk of developing CHD, an unhealthy life style is 
associated with higher health care costs than for people with a healthy lifestyle. 
 
Paper 2 is an assessment of the longer term labour market consequences of CHD. We compared labour 
market affiliation of CHD patients with a reference group of individuals with similar age, gender and socio-
economic characteristics in a duration analysis covering up to 23 years. The analysis showed that CHD 
patients withdraw from the labour market on average 0.8 year earlier than individuals in the reference 
group.  
 
Paper 3 is an economic evaluation of a newer treatment strategy (drug-eluting stents) for CHD. The study 
used register-based data to assess the long-term cost-effectiveness of the intervention. We found that the 
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incremental cost-effectiveness ratio was advantageous to drug-eluting stents after five years; however no 
firm conclusions on cost-effectiveness could be made based on this analysis since the observed difference 
in health outcomes was rather small. 
 
Paper 4 comprises an empirical assessment of the inclusion of survivor costs in the economic evaluation. 
Using register-based data for the entire Danish population, we derived age specific figures for both 
production and consumption with a view to including such figures in cost-effectiveness analyses. This paper 
contributes to the ongoing debate on inclusion of survivor costs by providing empirical figures on the 
magnitude of survivor costs. 
 
Overall, I found that the best available data should be used for analysing long-term costs and effects of 
interventions in the field of preventing and treating CHD. For this assessment, register-based data was used 
due to the applicability of results and the time frame of the analysis. The four papers demonstrate that 
there are important resource consequences of CHD in both the short and the long-term. 
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Danish summary 
Iskæmisk hjertesygdom (CHD) er en kronisk, alvorlig og potentielt livstruende sygdom, som har omfattende 
konsekvenser på flere niveauer. Først og fremmest sygdomskonsekvenser på det individuelle niveau, 
herunder sociale og psykologiske konsekvenser på kort sigt og økonomiske, blandt andet arbejdsmæssige, 
konsekvenser på længere sigt. Sygdommens opståen kan endvidere forårsage ændringer i livsstil, der kan 
påvirke forekomsten af andre livsstilsrelaterede sygdomme. 
 
I sundhedsvæsenet er der betydelige konsekvenser af CHD: En forholdsvis stor andel af de samlede 
sundhedsomkostninger vedrører behandling af CHD, og mange forebyggelsestiltag retter sig mod CHD og 
andre livsstilsrelaterede sygdomme. På samfundsniveau, dvs. udover sundhedsvæsenet, påvirker CHD 
patienternes arbejdsmarkedstilknytning, ligesom sygelighed og dødelighed har betydning for fremtidigt 
forbrug, både indenfor og udenfor sundhedssektoren. Ændringer i produktivitet og forbrug har 
konsekvenser udover det individuelle niveau. 
 
Denne analyse af konsekvenserne på kort og langt sigt af iskæmisk hjertesygdom fokuserer på økonomisk 
evaluering af behandling og forebyggelse af hjertesygdom. Mange økonomiske evalueringer er baseret på 
randomiserede kontrollerede studier (RCT), som ofte er begrænset til en kort tidshorisont. I denne 
afhandling argumenterer jeg for, at tidsperspektivet for økonomiske evalueringer skal være tilstrækkelig 
langt med henblik på, at alle relevante omkostninger og effekter inkluderes. Jeg argumenterer endvidere 
for, at data fra andre kilder end RCT kan inddrages med fordel, herunder især registerdata med en længere 
tidshorisont end randomiserede studier. 
 
Denne afhandling er baseret på fire videnskabelige artikler. Artikel 1 omhandler sundhedsomkostninger 
associeret med CHD og med en uhensigtsmæssig livsstil, med henblik på at kunne vurdere effekten af 
eventuelle forebyggende tiltag. Vi fandt, at sundhedsomkostningerne var statistisk signifikant højere for 
hjertepatienter end for ikke-hjertepatienter. Desuden fandt vi, at sundhedsomkostningerne blandt 
personer i risiko for at udvikle CHD var lavere for personer med sund levevis end med usund livsstil. 
  
Artikel 2 er en analyse af arbejdsmarkedskonsekvenser af CHD på kort og langt sigt. Vi sammenlignede 
arbejdsmarkedstilknytning blandt hjertepatienter med en referencegruppe af ikke-hjertepatienter, der var 
identiske med hjertepatienterne med hensyn til køn, alder og socioøkonomiske karakteristika. Vi 
analyserede arbejdsmarkedstilknytning over en periode på op til 23 år ved brug af overlevelsesanalyse og 
fandt, at hjertepatienterne forlod arbejdsmarkedet 0,8 år tidligere end personer uden CHD. 
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Artikel 3 er en økonomisk evaluering af en nyere, meget udbredt behandling af CHD, drug-eluting stents, 
der anvendes ved ballonudvidelse af forsnævrede koronararterier. Vi brugte registerdata og kunne dermed 
analysere omkostningseffektivitet på væsentligt længere sigt end hovedparten af tidligere studier på 
området. Vi konkluderede, at drug-eluting stents var omkostningseffektive efter en fem-årig periode, om 
end der ikke kan drages håndfaste konklusioner på basis af resultaterne, da forskellen i effekt mellem de to 
sammenlignede interventioner var ret lille.  
 
I artikel 4 anvendte vi registerdata til at beregne produktion og forbrug i et-års aldersklasser. Disse 
opgørelser kan anvendes som udtryk for de fremtidige økonomiske effekter af overlevelse. Beregningerne 
kan anvendes i økonomiske evalueringer ved inddragelse af fremtidige omkostninger. Artiklen bidrager til 
debatten om inklusion af fremtidige omkostninger i økonomiske evalueringer af sundhedstiltag ved at 
demonstrere effekten af at inddrage disse i økonomiske evalueringer.  
 
Jeg konkluderer at økonomisk evaluering skal inddrage de bedste data der er til rådighed. Jeg har anvendt 
register-data til at analysere interventioner der har til hensigt at behandle eller forebygge CHD, idet 
analysen derved fik en længere tidshorisont og resultaterne fik en øget anvendelighed. De fire artikler viser 
at der er store ressourcemæssige konsekvenser af CHD, både på det korte og det lange sigt.  
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I.  Introduction  
 
 
Coronary heart disease (CHD) is one of the most important causes of death and hospitalisation in Denmark 
as well as in most other countries. In addition, a variety of health care and health promotion interventions 
aim at treating, alleviating or preventing CHD. When analysing the resource consequences of CHD, it 
appears that there are significant consequences in both the short and the longer term. 
 
In health sciences, costs and effects of interventions as well as costs of an illness are often assessed over a 
short time period. Frequently, the effect of a health care intervention is measured in randomised controlled 
trials (RCTs) with a restricted time frame of e.g. six months or one year.  
 
The short-term consequences of CHD have been widely assessed, using RCTs and other data sources1-9. 
However, only few studies10-12 have considered costs and consequences beyond the first year. 
 
Use of register-based data allows for analysis of a longer time period, which may alter results substantially. 
In addition, register-based data can provide information of a different quality than trial data, for use in 
cost-effectiveness analysis. For chronic conditions such as CHD, disease progression, lifestyle changes, and 
decisions related to the condition, such as labour market withdrawal, may occur at a much later stage than 
one year13.  
 
Over a longer time period important costs and effects may arise both within and outside the health care 
sector, pointing to the significance of the perspective of the analysis. In addition, using perspectives 
narrower than that of the entire society for economic evaluation excludes important costs and 
consequences and may lead to inefficient resource allocations14. 
 
The main focus of this thesis is analysis of the costs and consequences of coronary heart disease, making 
the case for increased use of register-based data, inclusion of a sufficient time frame and adoption of the 
societal perspective. 
 
This thesis is structured as follows: First the overall research question is formulated and motivated. Chapter 
II describes the theoretical rationale for the assessment of costs and consequences in economic evaluation 
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and outline some of the key issues in identifying costs and effects in economic evaluation. In Chapter III, I 
assess and discuss the types of data sources that are applied in economic evaluations and focus on their 
advantages and disadvantages in particular when the long-term perspective is involved. Chapter IV 
provides a literature review of economic evaluations within the field of coronary heart disease, focusing on 
the perspective and time frame applied as well as the types of data sources used. In chapter V, I describe 
the methods and data sources used in the four papers, relating these to the main points of the preceding 
chapters. Chapters VI through IX list the main points from the four papers in the thesis. The four papers are 
attached as appendices. Chapter X concludes on the main themes of the thesis. 
 
Overall research question 
Coronary heart disease is one of the leading causes of death and hospitalisation throughout the Western 
world. In Denmark, the mortality from CHD was 317 per 100,000 men and 333 per 100,000 women in 
200515. Also, CHD was the most frequent cause of hospitalisation in Denmark with 1,786 admissions per 
100,000 men and 1,409 admissions per 100,000 women in 200515. Aside from the serious disease 
consequences such as hospitalisation or death, a number of other consequences follow a case of CHD. 
Hence, I focus on consequences in different time frames, where the short-term comprises the first year 
following an event, and the longer term reaches beyond this horizon. I also consider different perspectives 
of consequences, in particular the health care sector and the societal perspective. 
 
Short-term consequences of a CHD event comprise changes in the individual’s mental health, social life and 
lifestyle. In the longer term, the individual’s labour market affiliation may be affected, as well as their 
earnings and consumption. Since a heart patient’s lifestyle often improves as a consequence of disease, 
long-term morbidity may also change.  
 
Aside from individual consequences, morbidity and mortality from CHD also affects the societal level. In the 
short term, CHD impacts on health care costs related to CHD treatment16, while in the longer term other 
health care costs could change17. In addition, changes in patients’ labour market affiliation, earnings and 
consumption cause changes at the societal level13;18.  
 
The consequences of CHD are thus fourfold: Consequences for the individual in the short-term, 
consequences for the individual in the long-term and societal consequences in the short and long-term. All 
four dimensions include medical, economic and other consequences. Assessment of the variety of 
Introduction 
 
 
 Page 17 
consequences is important when analysing costs and effects of health care and health promotion 
interventions.  
 
The first key issue of this thesis is the importance of including long-term consequences in the economic 
evaluation of health care interventions. Focus on the short-term alone could lead to ineffective decisions as 
future costs and effects may be significant. For health care interventions, the time frame of the analysis 
should be sufficient to capture all relevant costs and effects. In health promotion, costs appear both in the 
short-term as directly related to the intervention, and in the long-term, as savings resulting from improved 
health and longevity. 
 
The second and third key issues relate to the first. As register-based data often cover a longer time span 
than trial data, register data may be as applicable for use in economic evaluations as trial data. The real 
world applicability of register-based data provides another central argument for use of these data.  
 
Thirdly, an expanded time frame of analysis necessitates inclusion of consequences beyond the health care 
sector perspective. Decisions based on an analysis applying a perspective that is narrower than societal, 
could lead to inefficient resource allocations. 
 
The principal motivation for this thesis then becomes: identification of the best available data and the most 
appropriate time frame and perspective for the economic evaluation of health care and health promotion 
interventions, focusing on prevention, treatment and rehabilitation of coronary heart disease.  
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II.  Methods for economic evaluation 
 
 
Economic evaluation of health care interventions comprises analysis of economic and other consequences 
of disease and usually compares two or more treatments of a particular disease or disorder. This chapter 
outlines the theoretical rationale for economic evaluation and some of the most widely used methods. 
 
Economic evaluations of health care interventions most often take the form of cost-effectiveness analyses 
(CEA)19. In CEA costs associated with different interventions are related to the effects of the interventions20. 
Effects are measured as life years gained, quality-adjusted life years (QALYs) gained, or in a few cases a 
more clinical measure such as decreased blood pressure.  
 
Cost-benefit analysis (CBA) differs in nature from CEA as benefits in CBA are measured in monetary terms. 
In CBA, net benefit is obtained by subtracting the costs from the monetary value of the effect. Willingness 
to pay (WTP) estimates are most often used as the monetary value of the effect of the intervention. The 
use of CBA in the field of health care is rather limited20-22, but as CEA derives from CBA, the theoretical 
foundations of CBA is outlined below. Further, the main elements of economic evaluation are defined. I will 
describe the process of identification of costs and effects and some key issues of these processes, as well as 
argue for the importance of including long-term costs and effects. This chapter also introduces some of the 
existing recommendations for CEA, including the 1996 US Panel reference case23. Finally, I will briefly 
discuss the topic of cost-of-illness analysis (COI). 
 
The rationale of CBA and CEA  
CBA rests on traditional welfare theory, while CEA is not as closely linked to welfare theory. Traditional 
welfare theory is mainly concerned with the societal desirability of different resource allocations24. Society 
is defined as a group of individuals and the societal welfare function can be defined as some form of 
aggregation of each individual’s welfare. The recommended societal perspective for economic evaluations 
derives directly from the notion of societal welfare.  
 
It is assumed that individuals seek to maximise their own utility subject to a budget constraint which is 
determined by their income. In a group of individuals, such as a society, welfare is a function of the 
individual utilities21. In the following, the utility from health is used as an example of individual utility. 
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The individual utility from health can be expressed as a function of income and conditions influencing on 
utility or the health state. The individuals will aim for the health state that maximises their utility subject to 
the budget constraint given by their income. In a group of individuals, utility functions are not comparable 
because different individuals may assign different value to health. Therefore utility maximisation in a 
society, where more than one individual is involved, becomes challenging. For two or more people, a 
distribution of goods is said to be Pareto efficient when one individual cannot increase her utility without 
making the others worse off. A Pareto improvement occurs when one individual increases her utility while 
the other individual’s utility is unchanged or improved25.  
 
The concept of Pareto efficiency appears rather restrictive. Most redistributions of income and 
consumption are likely to make some individuals worse off. Redistribution of income takes place at the 
societal level in the form of taxes and distribution of public goods and services such as health care. Pareto 
efficiency does not ensure a fair income distribution; in fact a very unequal income distribution can be 
Pareto efficient25. Based on the recognition that some individuals may have access to plenty of 
commodities but may not need that much, while other individuals may need more than they have access 
to, the notion of compensating was introduced25. Some people may be healthy and need only little health 
care while having access to more health care than they need. For others the situation is the reverse and 
therefore they will be interested in trading with those individuals having an abundance of health care.  
 
The Kaldor-Hicks compensation criterion defines a situation as being efficient if those benefiting from the 
change in distribution can fully compensate those losing, and still experience a benefit. For each individual, 
the utility as a function of income minus a compensating variation (CV) and the changed characteristics of 
the health state should equal the utility of the income and characteristics of the former situation. CV could 
be positive, if the new situation implies an improvement for the individual. CV then represents the 
individual’s willingness to pay (WTP) for the improved health state. For deteriorations in health, CV would 
be negative and the interpretation of CV is the willingness to accept (WTA – an income gain) the 
deterioration in health. The new situation is considered optimal according to the Kaldor-Hicks criterion, if 
the sum of compensating variations over all individuals exceeds zero25;26.  
 
The Kaldor-Hicks compensation criterion is hypothetical rather than actual; in other words if the 
compensation can take place hypothetically, the new situation is efficient. From the equation of 
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compensating variation, the rationale for cost-benefit analysis can be derived directly22;26-28. The difference 
in preferences between the new and the former health state is expressed in monetary terms, via the WTP 
or WTA25. This constitutes the benefit of the new situation and is used to compute net benefit by 
subtracting costs. The cost-benefit equation expresses the net benefit as benefits minus costs. 
 
The Kaldor-Hicks compensation criterion and its application in health care are based on the rather rigid 
assumption that all individuals in the society have identical marginal utilities of income25;29. Whereas 
utilities as such are not added or compared across individuals, the monetary expression of their 
preferences are added and assumed of equal value. The implication of this is that the rich and the poor 
should place the same utility on a marginal change in income. Therefore compensation using the monetary 
terms of cost-benefit analysis is based on an assumption that may not be fulfilled, which is the rationale for 
deviating from the monetary expression of benefits. A less theoretical motivation is the technical and 
practical difficulties in expressing benefits in monetary terms within health22;30.   
 
In cost-effectiveness analysis, effects are not measured in monetary terms. Effects or outcomes of health 
care interventions usually express a health gain. The deviation from monetary expression of benefits also 
makes the connection to traditional welfare theory unclear25;28. Instead of subtraction, CEA uses division to 
express the cost per health gain27;31. In addition, CEA maximises societal welfare subject to a budget 
constraint, whereas CBA maximises net (monetary) benefit. The presence of a budget constraint also 
represents an important difference between CEA and CBA. Further, as economic evaluation is used for 
decision making, the results should relate to what the health gain is worth20. In CBA, the value of the 
intervention is produced by the CBA-figure while for CEA the results need to be compared to a threshold or 
a league table32 in order to conclude on the value20. 
 
The ratio of costs divided by effects is called the cost-effectiveness ratio. When two (or more) interventions 
are compared, the analyst will focus on the incremental cost-effectiveness. Therefore the cost difference 
between interventions is divided by the effect difference to obtain the incremental cost-effectiveness ratio 
(ICER)31. 
 
While the relation to traditional welfare theory may have become unclear in CEA, the overall rationale 
remains maximisation of societal welfare. Adopting a perspective narrower than a societal one creates an 
additional problem. Which utility should be maximised by the health care production function, if not the 
societal? The budget constraint however relates to the health care budget and generally not beyond. 
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In CEA, the utility that is maximised stems from the health gain caused by the intervention. In other words, 
other utilities are disregarded. E.g. process utility being the utility gained (or lost) by patients or 
caregivers20;33;34 in the process of reaching the health state, is generally not considered. 
 
The intuition of CEA is to achieve the maximum amount of health for a given budget35, or alternatively to 
achieve the cost of reaching a desirable level of health. CEA is a tool for decision-making, as it provides a 
ranking of interventions according to the cost per effect. Effect measures in cost-effectiveness are outlined 
below.  
 
Effect measures 
Ideally, CBA should be used for economic evaluation because it maintains the theoretical rationale35, cf. 
above. However the monetary expression of benefits in CBA is seldom feasible and therefore most 
economic evaluations in health care apply CEA, using QALYs or other non-monetary measures as the effect 
measure. 
 
When CEA is used instead of CBA, the utility expressed by the benefit measure of CBA is expressed by a 
non-monetary measure. The effect measure either expresses final outcomes, such as quality-adjusted life 
years (QALYs)27, gain in life years (LY) and healthy year equivalents; or intermediate outcomes such as a 
lower blood pressure (in e.g. the treatment of hypertension). The latter does not reflect health or health 
gain and should be translated into a final outcome in order to calculate the cost per health gain. The 
intuition behind this is that low blood pressure is not a goal in itself, while the improvement in health 
caused by the lower blood pressure is the actual goal of the intervention36. Thus, an intervention that 
reduces blood pressure should be prioritised only because medical evidence suggests that a low blood 
pressure improves health, which is the true aim of the health care intervention. The cost-effectiveness 
analysis should therefore adopt a time horizon that allows for analysis of final outcomes such as QALY or 
LY. 
 
For the final outcomes, the main difference between QALYs (and similar measures) and LYs, is that QALY, 
being a compound measure composed of a difference in LY and a change in health related quality of life 
(HRQoL)37;38, is preference-based39. The HRQoL instruments are used for describing different health states. 
Individuals’ preferences for these health states can be revealed through use of e.g. the standard gamble 
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method40. Therefore, some HRQoL instruments can be converted to preference-based measures40, and 
differences over time or between interventions in HRQoL can be measured36. A gain in HRQoL is multiplied 
by the gain (if any) in life expectancy to obtain the number of QALYs gained by each intervention. The QALY 
gains of the compared interventions are subtracted from each other to form the denominator of the ICER. 
 
In some studies, data on HRQoL are not available, as participants were not asked or could not complete the 
questionnaire due to their condition. Sometimes in the event that one lacks HRQoL data, data from other 
studies can be found in the literature or imputed41. Otherwise LY can be used as the effect measure. 
 
Costs 
While health outcomes in CEA are measured in terms of QALYs or other non-monetary measures, resource 
consequences of the analysed health care intervention are measured in monetary terms. Costs are 
identified as the change in resource use caused by the intervention, or, more precisely, the change in 
resource use from implementing the intervention compared to usual care42.  
 
Identifying costs 
The identification of costs in economic evaluation includes decisions on the perspective of costs and the 
time frame of the analysis, including the concept of survivor costs.  
 
Perspective of costs 
The aim of the economic evaluation is to inform decision makers of the comparative cost-effectiveness of a 
health care or health promotion intervention43; therefore the perspective of the analysis relates to the 
perspective of decision makers. Decision makers are based in different settings and therefore form 
decisions from their own perspective of responsibility44. Chapter IV identifies the following common 
perspectives in economic evaluation: the societal perspective, the health care sector perspective and the 
third party payer perspective. For an analysis of e.g. coronary angioplasty, an analysis from the health care 
sector perspective would comprise costs during admission and rehabilitation, as well as pharmaceuticals 
and use of general practitioners following discharge. A third party payer perspective would include health 
care costs and also costs in the social sector, such as home care or nursing homes. Examples of third party 
payers are the German ‘Krankenkassen’ and the American Medicaid or private health insurance companies. 
In Denmark, a third party payer would be the health care provider; which would have a similar perspective 
to the health care sector, unless the third party payer takes an interest in shifting costs from one public 
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authority to another (e.g. from regions to municipalities). The main difference between the societal 
perspective on one side and the health care sector and third party payer perspectives on the other, is the 
inclusion of productivity and consumption changes, patient time costs, and economic effects on others, e.g. 
time spent by the patient’s family.  
 
Most economic evaluations in health care apply the health care sector perspective or the third party payer 
perspective (this is elaborated in chapter IV). Inclusion of only health care related costs in the economic 
evaluation ignores the impact of the intervention in other sectors. Perspectives as narrow as the health 
care sector may render flawed results, as e.g. costs for the hospital department may not reflect true costs if 
costs are shifted to other departments, outpatient treatment or practising specialists. Most importantly, a 
single sector perspective may lead to a result that does not maximise the welfare of the whole society but 
only the welfare confined to that sector14;44. This contradicts the welfare economics position that societal 
welfare should be maximised, cf. above. Further, a resource allocation that appears optimal within a single 
sector may be suboptimal or inefficient from the perspective of the entire society. 
 
While the health care sector and the third party payer perspectives are not identical, they both maintain 
focus on health care related costs. The societal perspective presents a different approach than the health 
care sector related perspectives, but seems to be defined in various different ways. Some studies apply the 
societal perspective defined by the US Panel, in which income effects (consumption and production 
changes) are not considered beyond the so-called time costs; the time spent by patients in treatment21;45. 
The recommendations of the US Panel are described below.  
 
In addition to the impact on production and consumption, the societal perspective potentially comprises a 
number of other cost components: costs of informal care-giving, i.e. family members caring for an ill 
person; and costs of administrating social pensions and benefits for patients leaving the labour market due 
to the analysed condition14;44. These cost components are seldom assessed, mainly due to important 
measurement difficulties.  
 
While the definition of costs from a societal perspective seems somewhat ambiguous, this is also the case 
for health care costs, although to a lesser extent. Future unrelated health care costs are sometimes not 
included (this is elaborated in chapter IV). The distinction between related and unrelated health care costs 
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is unclear in many cases, rendering identification of unrelated health care costs difficult. Also, the precise 
definition of the health care sector may differ between countries. 
 
Time horizon 
 ‘Ideally, the time horizon should be chosen in such a way that all cost consequences of the intervention 
under study can be taken into account in the analysis’ 
Brouwer et al (2001), p. 7114. 
In the design of a CEA study, decisions regarding the time frame of costs and effects are central. Both costs 
and effects can occur immediately as well as in the long-term. For prevention, most costs and effects occur 
at a later stage46. Also for health care interventions, relevant costs and effects can be identified several 
years after the intervention. 
 
The long-term of a health care intervention may be different from the short-term. An economic evaluation 
of a health care intervention that covers a short time frame may not include all relevant costs and effects. 
This was a crucial message resulting from the analysis in paper 3, which rendered different results when the 
time horizon was expanded. To account for the insufficient information relating to the short time frame of 
many studies, they often include a decision model (Markov model or similar), which extends the analysis 
time horizon. In such cases the analysis time frame is expanded while the study time frame remains short. 
In the case of the study time frame being too short, the model may render insufficient results. 
 
The time frame of costs is as relevant as the time frame for effects and could, in fact, alter results 
significantly. Lifetime costs depend strongly on length of life47. An intervention that increases life 
expectancy causes health care costs and savings at higher ages, which may or may not be related to the 
disease; e.g. a coronary angioplasty patient that lives long enough to suffer from cancer at a high age.  
 
The nature of cost components is different in studies with relatively long time frames. In the cost 
measurement, it may no longer make sense to distinguish between fixed and variable costs, as fixed costs 
become variable14.  
 
Compared with health care interventions, health promotion interventions will often have more important 
cost consequences in the long-term than in the short-term. An intervention aiming to prevent alcohol 
abuse will, if successful, decrease the incidence and mortality from alcohol-related diseases several years 
after the intervention. Thus, there is a health care cost saving associated with the intervention, but only in 
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the long-term. The people that live longer and do not suffer from alcohol-related diseases will also at some 
stage need hospital treatment for other diseases, such as CHD. A moderate alcohol consumption is known 
to decrease the risk of CHD48. Therefore, there may be other long-term health care costs associated with 
the health promotion intervention.  
 
Consequently, if the analysis time frame of the health promotion intervention was short, e.g. one or five 
years, neither the cost figure nor the effect measure would be complete. The study period needs to be 
sufficient and can be combined with modelling. The same reservation applies to health care interventions 
that may incur related or unrelated health care costs as well as survivor costs at a later stage.  
 
Survivor costs 
Survivor costs, also called future costs, occur over a longer time perspective than the actual intervention. 
They comprise downstream health care costs, unrelated health care costs, production and consumption 
changes49-52.  
 
A long-term consequence of health care and health promotion interventions is a gain in LY, in most cases 
quality-adjusted, i.e. QALY. In added years of life, the individual that gains from the analysed health care or 
health promotion intervention may contribute to production and will, in any event, maintain a 
consumption of health care and non-health care goods and services. It is still being debated in the health 
economics literature whether these cost components should at all be included in the cost calculation49-53. 
For interventions that improve health without having an impact on life expectancy, consumption and 
production could also change as a result of the improved health.  
 
The magnitude of survivor costs can either be assessed in a long-term register-based or cohort analysis, or 
computed as the increased longevity known from the intervention, times an average figure for survivor 
costs generated from the background population, such as the costs computed in paper 4. Paper 4 also 
demonstrated that inclusion of survivor costs can alter the cost estimate considerably, underlining the 
importance of the perspective and time frame of the analysis.  
 
Cost measurement 
This section is concerned with issues relating to the actual quantification of costs, comprising top-down vs. 
bottom-up costing, including the concept of activity based costing. 
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Top-down vs. bottom-up costing 
In top-down costing, the costs of e.g. a specific health care service are derived as the total costs of 
providing the service, divided by the number of patients using the service. The cost figures are usually 
based on accounting figures from the health service provider54. Thus, top-down costing refers to estimation 
of average unit costs using available accounting figures. These unit costs are used for multiplication with 
the number of patients participating in the analysed health care intervention. Due to the use of accounting 
data, top-down data collection always takes place retrospectively44. Costs in the health care sector are 
divided into fixed and variable costs, where the former category typically comprises buildings and large 
equipment and the latter comprises wages and other current costs, such as pharmaceuticals. The top-down 
approach often includes some elements of fixed costs, while this is not the case for bottom-up costing. In 
the short-term, fixed costs are often not included in the cost figure44. For long-term analysis however, 
including fixed costs may be more appropriate, as the distinction between fixed and variable costs becomes 
unclear in the long-term14. 
 
Bottom-up costing is considered less feasible than top-down costing14. The bottom-up costing approach 
follows a number of participants and records their resource use, arriving at a more precise figure for 
average costs and also obtaining figures for variance between patients. In addition, bottom-up cost figures 
can distinguish between costs for patients successfully completing the intervention and drop-outs. Health 
care costs unrelated to the intervention can be excluded if the perspective of the analysis prescribes it. 
Further, bottom-up costing can be carried out prospectively, if it is included in the design of e.g. a trial. 
 
Most often CEA are based on top-down figures due to the feasibility14;44 and availability of cost figures or on 
a combination of top-down and bottom-up approaches54. The latter, mixed approach, may however suffer 
from weak external validity due to incompatibility of top-down and bottom-up figures44. 
 
While bottom-up costing appears to be the most precise approach to cost measurement, it may render 
underestimated cost figures as some cost components could be ignored, including fixed costs in analyses of 
longer time perspectives.  
 
Activity based costing 
The activity-based costing approach was introduced as a link between health care services and costs, based 
on the notion that health care services per se do not consume resources, but activities, and these employ 
Short and long-term consequences of coronary heart disease 
 
 
 
Page 28 
 
resources55. Activities hence became a link between services and resources. E.g. a health care service such 
as a treatment of angina consists of several activities, including bypass surgery, anaesthesia, intensive care 
unit, nursing, x-rays, medication, etc. For each well-defined activity, the resource use is identified. Each 
discharge is then composed of activities, all with a well-defined resource usage. Activity-based cost figures 
represent a refinement of the bottom-up costing approach since it is based on the accounting principle of 
full absorption costing, i.e. both fixed and variable costs are included44. 
 
 
Valuation of costs 
This section relates to valuation issues of the cost calculation in cost-effectiveness analysis, including the 
concepts of opportunity costs and unit costs, as well as discounting. 
 
Opportunity costs 
The costs in cost-effectiveness measurement are valued as the opportunity costs or the shadow price of the 
intervention56. In terms of Pareto efficiency, the opportunity cost is the net benefit foregone in order to 
obtain the health gain associated with the intervention57. Health care costs, being the time spent by health 
care personnel, use of pharmaceuticals and medical equipment, are valued by the best alternative use of 
resources, i.e. the opportunity cost of diverting resources from their best alternative use14;58. 
 
Generally, costs represent a use of resources often valued by market prices or expenditures or accounting 
figures. In the ideal situation, cost information would be derived from the market equilibrium in which 
prices reflect opportunity costs. However in health care, prices may not reflect opportunity costs per se14;44 
due to market distortions, or may even not be present14. The measurement of costs in cost-effectiveness 
analysis should overcome this challenge by adjusting market prices or using other proxies for opportunity 
costs56.  
 
Unit costs 
For measurement of the costs of a health care intervention, the analysis should identify relevant units 
required for the intervention (e.g. physician work hours), and a unit cost for these units. In market 
equilibrium, the wage of the health care professional equals the marginal benefit of their production. The 
unit cost is then the gross hourly wage paid to the employee. For other cost items unit costs should in 
principle be derived from market equilibrium prices if such exists. In effect prices of materials and 
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equipment are valued at their market prices assuming that the se are sold in a perfect competitive market 
where the market price is equal to marginal production costs.  
 
Unit costs can be derived either through bottom-up costing exercises 54 or through top-down where cost 
figures are derived from expenditures, charges or tariffs, used under the appropriate assumptions14;44. 
 
Discounting 
Costs in economic evaluations covering more than one year should be discounted to reflect that the time 
preference for costs in the future differs from costs in the present. A similar time preference applies to 
effects. 
 
While there is no disagreement on the necessity of discounting, there has been some debate regarding the 
magnitude of the discount rate59, including whether costs and effects should be discounted at the same 
rate60. The US Panel recommends use of 3 percent p.a. as the discount rate for both costs and effects56.  
 
Application of cost valuation 
The health care sector is characterised by market distortions, cf. above. For this reason, it is necessary to 
make some assumptions in the cost measurement and valuation. A common assumption is to use charges 
as proxies for unit costs44. This occurs in the Danish primary health care sector and in countries with 
insurance based health care. However, charges may not equal costs, because they either exceed true costs, 
in the presence of profits, or are lower than true costs, when treatment is subsidised44. Charges should only 
be used in the cost computation together with thorough knowledge of the relation between costs and 
charges61. This issue is more central in countries such as the US where health care services are market 
based. For this reason cost-to-charge ratios have been developed in the US44. 
 
In the Danish health care sector, tariffs are widely applied. Hospital treatment is provided free of charge for 
the patient; however hospitals are budgeted according to their production, measured in DRG-points 
(diagnosis related groups). For each DRG, a tariff is calculated, based on average variable costs62. The tariffs 
represent an attempt to create a market; however the tariffs apply universally and therefore ignore 
differences in the service provided and differences in opportunity costs between hospitals. Possible 
economies of scale are also disregarded as the same tariffs apply to the same treatment, regardless of 
hospital size. 
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In addition, cost figures based on tariffs are not completely correct because tariffs are used for 
remuneration in the health care sector, and could as such reflect the bargaining power of trade unions or 
employers rather than true resource use44. In the Danish system, however, tariffs are used universally and 
are not subject to bargaining, therefore they can, under appropriate conditions, be considered reasonable 
proxies for true cost figures14.  
 
Recommendations for CEA 
During the 1990s, a growing body of CEA put focus on the need for a common methodology and 
terminology in economic evaluation. As a response to this need, the so-called US Panel in 1996 issued a set 
of recommendations for economic evaluations of health care interventions45. Since then, a number of 
countries issued their own guidelines for economic evaluation, often within the context of health 
technology assessment. The UK NICE guidelines63 are widely used and discussed also in other countries. The 
Danish and Swedish guidelines64;65 differ from the NICE recommendations in their recommended 
perspective, and from the US Panel in their interpretation of the societal perspective. 
 
This section concentrates on the US Panel reference case for CEA23. The reference case comprises, inter 
alia, the following elements45: 
 Costs and health effects should be assessed from the societal perspective 
 The impact of production changes on the individual should be captured by the HRQoL instruments 
used for the QALY estimation. 
 Productivity effects on others, including friction costs, should be included, if significant. 
 Time costs should be included, measured by wage rates. 
 Resources should be valued by their opportunity cost, and assessed from a long-term perspective. 
 Future health care costs and non-health care consumption should in theory be included, but this 
may not be possible. 
 The time frame should be sufficient to capture all relevant costs and effects 
 Evidence for effectiveness may be obtained from a variety of data sources (RCTs, registers, other). 
 
The US Panel argued that future income changes, as discussed above under survivor costs – or at least 
productivity gains for the individual – should not be included in the cost effectiveness measurement, as the 
benefit of the increased production is already accounted for. The explanation for this argument relates to 
the QALY calculation. The respondents replying to the time trade-off questions of EQ-5D or similar are 
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asked to imagine and subsequently value, a certain health state25;36;40. In doing so, they may also consider 
the changes in productivity and consumption following from that health state, and take these into account 
in their valuation. Indeed the US Panel recommended that HRQoL was measured by an instrument that 
took future productivity changes into account. The US Panel found that if the utility arising from a 
productivity gain is part of the QALY, it should not be a part of the cost computation as well. Including the 
same item in numerator and denominator would be double counting45;56. 
 
The Panel did briefly consider the impact of productivity changes for individuals other than those gaining 
from the intervention. These should be included, if significant. In particular, friction costs should be 
incorporated if feasible. Friction costs cover the costs to employers when an employee leaves her position 
due to death or illness and a new person has to be recruited and trained66. 
 
For future health care and non-health care consumption, the US Panel argues that the most appropriate 
option is to include these future cost components, but due to feasibility considerations, one could choose 
to exclude them56. 
 
As argued above, the survivor costs of an intervention include costs to others and are not identical to the 
benefit for the individual. When the cost effect of surviving is divided into the impact on the individual and 
the impact on others, it appears that the latter is not included in the QALY, while it is debatable whether 
the impact on the individual is included in the QALY49-51;67-69. Therefore for at least some of the survivor 
costs, inclusion in the numerator of the cost-effectiveness ratio would not be double counting. Instead, 
survivor costs form an integral part of the long-term cost, and should be included when the time frame of 
the study is long enough. In many cases though, data for this inclusion may not be available.  
 
Aside from the excluded productivity costs, the US Panel argued for the adoption of a societal perspective, 
relating to the welfare theoretical rationale of economic evaluation. A narrower perspective could lead to 
inefficient resource allocations70. The perspective of the economic evaluation appears to be the area where 
recommendations differ most. The NICE guidelines in the UK recommend application of the NHS 
perspective63, hence leaving out costs and effects outside the health care sector. The Danish and Swedish 
guidelines recommend the societal perspective, while defining this somewhat broader than the US Panel, 
as they include productivity changes and other survivor costs64;65. 
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The time frame of an economic evaluation should, according to the US Panel, be sufficient to capture all 
relevant costs and effects. Costs and effects occur at later stages; also the use of final outcomes (QALYs and 
LY’s) dictates a longer time frame. 
 
While quoting hierarchies of evidence71  (such hierarchies are discussed in chapter III), the Panel was rather 
pragmatic in their approach to data sources and simply stated that evidence may be obtained from a 
variety of data sources, in their recommendation for economic evaluation.  
 
Cost-of-illness 
The so-called cost-of-illness (COI) studies measure health care costs and future costs of a given disease or 
disorder, but do not relate costs to effects17;46. In a COI study, the costs of a given disease or risk factor is 
calculated, either on the basis of prevalence figures in burden of disease studies, or as costs per new case 
of the disease in question. The prevalence based COI is based on questions such as: How much does 
coronary heart disease cost the Danish society per year? On the other hand, incidence based COI results in 
a potential saving, if one case of coronary heart disease is avoided e.g. through successful prevention 
measures. 
 
COI studies often apply a similar methodology for cost assessment as cost-effectiveness studies, but do not 
relate to a specific health care or health promotion intervention. 
 
In the prevalence based form of COI, the average annual health care costs, social costs and productivity 
costs of the disease are calculated (and sometimes even assumed), and multiplied by the prevalence in a 
given year72. As this approach disregards the differences between incident cases and people that have been 
living with the disease for ten years, the resulting figures cannot be used for expressing costs in CEA. The 
applicability of COI in decision making is rather limited because of COI not relating to effect measures. 
Therefore decisions based on COI results could lead to inefficient and suboptimal health care resource 
allocations73. E.g. if decision makers are presented with a COI concluding that CHD is very costly, they could 
choose to spend resources on interventions that aimed to treat or prevent CHD but were not cost-effective. 
 
A more refined COI analysis would, upon identifying people with the analysed condition, trace their health 
care costs and other cost components. Then, by identifying a comparable group of people without the 
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condition, calculate attributable costs as the average cost for people with the condition excluding average 
cost for people without the condition.  
 
Even though the attributable cost method measures actual costs and thereby excludes costs that are 
irrelevant to the condition, the use of COI results still appears rather limited. A COI usually presents results 
as the annual costs to society of a given disease or condition. However, the condition may be preventable 
or curable if an intervention is timed appropriately. If, e.g., the COI result is the lifetime cost of a newly 
diagnosed case of CHD, it can be applied in an assessment of whether prevention of CHD is cost-effective. 
Paper 1 provides such cost figures16. Or, if the COI assesses lifetime cost of new cases of myocardial 
infarction, it can be used for analysis of the cost-effectiveness of angioplasty.  
 
An example of COI is shown in a recent study of obesity46, which came to the result that, in a lifetime 
perspective, normal weight people incur more health care costs than obese people. Therefore, when 
aiming to minimise costs, obesity should not be prevented. The authors point out that the aim of health 
care was never only to reduce costs but also to increase health, and, from that perspective, there is still a 
case for preventing obesity. The main finding, which is reflected in the subtitle of the paper: ‘Prevention no 
cure for increasing health care costs’, relates to the finding of longer life expectancy amongst normal 
weight people than amongst obese and suggests that cost computations by themselves have little value as 
absolute measures46. Since health care costs are related to age, the older people become, the higher their 
health care cost per life year, which is illustrated in paper 4.  
 
Focusing on costs alone and comparing lifetime costs of obese people to those of normal weight people 
could lead to the strange conclusion that obesity incurs a societal gain. If, on the other hand, the costs of 
obesity were used in relation to the outcome of an obesity-preventative intervention, being a gain in LY or 
QALYs, this relative measure would provide decision makers with a tool for choosing between 
interventions.  
 
Contrary to COI measures, the cost-effectiveness ratio provides decision makers with a tool for comparing 
interventions with each other, with usual care and with no intervention22;74. COI can, if used correctly, be 
used for cost minimisation purposes, rooted in accounting rather than economic theory, or political 
organisations can use COI analyses for focusing public or political attention on a specific disease or 
condition.  
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Summary 
In this chapter I have outlined the theoretical framework of CEA and some of its central issues. I have 
introduced the concepts and definitions of effectiveness and costs, as well as the US Panel Reference Case 
for CEA. 
 
CEA is derived from CBA that rests firmly on welfare economics. This association prescribes that the most 
appropriate perspective for economic evaluations is the societal perspective. 
 
In addition, it is of central importance that the economic evaluation covers a time frame that is sufficiently 
long enough to render results on final outcomes, preferably QALYs as they are preference based.  
 
Finally, the rationale of CEA does not dictate use of a particular data source. Therefore, data sources used 
for economic evaluation do not need to be trial-based. 
 
I now turn to an assessment of the data sources for costs and effects in CEA.  
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III.  Evidence for economic evaluation  
 
 
In clinical epidemiology, the main focus is the relation between exposure and outcome. In the case of 
health care interventions, that would be the relation between treatment regime and effect or efficacy, 
meaning the isolated effect difference between treatment regimes. The choice of data for these analyses 
traditionally follows a hierarchy of data sources in which the randomised controlled trial (RCT) is on top. 
This hierarchy originates from clinical epidemiology and exists in a number of versions71;75. 
 
Meanwhile, the economic evaluation focuses on both costs and effects. In addition, measures of 
effectiveness, the real-world difference between treatment regimes, may be of higher value to the 
economic evaluation than measures of efficacy. 
 
‘*+ our philosophical notion is that; (1) an economic evaluation is only as good as the data it is based upon, 
but (2) economic analysts must do the best they can with the available data. ’ *Authors’ emphasis+ 
Drummond et al (1997), p 23420. 
 
Issues other than adhering to a hierarchy may dictate the choice of data for economic evaluations, 
including applicability and validity. Drummond et al (1997)20 discuss the validity issue in their assessment of 
which data are applicable for economic evaluations. They state that the data from RCTs often have a high 
degree of internal validity while a restrictive protocol can impact negatively on the external validity.  
 
Internal validity pertains to the strength of conclusions on efficacy or comparability of the analysed 
treatments. When the economic evaluation compares two treatments, its results should reflect differences 
between costs and effects of treatments and not differences between patient groups or other statistical 
noise. When the study has a high ratio of statistical signal to noise, it is said to have a high internal validity.  
 
External validity relates to the applicability of results. If a trial finds that a particular treatment is superior to 
its alternative, physicians will tend to choose this treatment in their clinics. The external validity is directly 
associated with the trial results being replicable in an unselected population. 
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In this chapter, use of different data sources in economic evaluations is described and discussed, focusing in 
particular on validity and applicability. 
  
The Randomised Controlled Trial 
‘Randomized controlled trials (RCTs) are generally accepted as the most powerful tool for assessing the 
effectiveness of interventions, medications, or procedures.’ 
Mandelblatt et al 1996, p. 14241 
 
The randomised controlled trial (or randomised clinical trial: RCT) is defined as a comparative study of two 
(or more) treatments in a controlled setting. One treatment arm can be conventional care or placebo, 
however the presence of more than one treatment arm is a central feature of the RCT. Further, participants 
have to give informed consent before enrolling, they have to fulfil a certain set of eligibility criteria, and, 
most importantly they are randomised to treatment arms. Randomisation is considered necessary in order 
to avoid differences between treatment groups that could influence results.  
 
The RCT sits at the very high end of the hierarchy of clinical evidence76;77. A large, well designed RCT 
provides a high internal validity of results. This means that for patients in everyday clinical life that are 
identical to trial participants, the trial result provides information on the best treatment. Conclusions on 
efficacy or outcomes based on RCTs are used widely, also in economic evaluations, often with little 
recognition of the clinical applicability of results.  
 
RCTs can be more or less restrictive and more or less protocol-driven. By a restrictive RCT is meant that the 
selection of patients for the trial is subject to a number of conditions. A very protocol-driven trial will tend 
to deviate from the everyday clinical setting to an extent that the external validity is potentially weakened. 
It is a common feature of trials that a certain age group is selected for the trial and that participants should 
be free of other diseases. Participants in a trial have to provide informed consent, which in some cases can 
contribute to selection bias. 
 
The term selection bias refers to bias in the selection of individuals for a trial impacting on the findings. 
Selection bias can also occur in other types of studies, except for studies in a completely unselected 
population and where response or consent is not required. However for RCT the selection bias often relates 
to participants being ‘too healthy’ that is, more healthy than the average patient suffering from the 
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investigated disease41. Related to the issue of selection bias is attrition bias, arising when trial participants 
discontinue participation to a different degree in the treatment arm compared to the control arm78. 
 
In the event of selection or other bias, the results of the RCT will suffer from lack of external validity. 
Transferring results to clinical use becomes difficult, as the participants of the trial are not comparable with 
‘normal’ patients. Clearly the usefulness of RCTs is limited when the external validity is poor. Drummond et 
al (1997) argues in favour of “pragmatic” trials, where the conditions are relaxed so as to increase the 
comparability with unselected patients in everyday clinical life20.  
 
Pragmatic trials are trials that are designed so as to resemble the ‘real world’ to a larger extent than 
‘explanatory’ trials focusing on evidence for efficacy. This latter type of trial tends to create an ideal setting 
that is not easy to generalise to everyday clinical life. The pragmatic trials were introduced in order to 
reduce this perhaps most important weakness of RCTs. Pragmatic trials aim explicitly at applicability in real 
life settings, and report their results in order to assess applicability79. Therefore, the main difference 
between pragmatic trials and explanatory trials is the inclusion criteria. The pragmatic trial maintains 
randomisation but does, due to the relaxed inclusion criteria, present a more heterogeneous study 
population. The Beich et al (2007)80 study provides an example of pragmatic trials. They focused on an 
intervention aimed at preventing alcohol abuse. Inclusion criteria were rather relaxed and masking or 
blinding was not feasible due to the study set-up in general practice. 
 
The difference has been explained as explanatory trials focusing on efficacy and pragmatic trials on 
effectiveness81. Others have argued that, in the event of a pragmatic trial finding no effect, it is difficult to 
establish whether the reason for this is the design of the trial or if there would have been no effect in an 
explanatory setting82. This argument applies to significant findings too and relates to the potentially weaker 
internal validity of pragmatic trials.  
 
The internal validity is probably even weaker in cluster-randomised trials. A cluster-RCT is a trial, in which 
intact groups of eligible patients are randomised to different treatment arms, as opposed to the standard 
RCT where individual patients are randomised83;84. The groups or clusters are often defined as 
organisational units, such as hospitals or GP practices. As such, the cluster-RCT may be more similar to a 
register-based study, where differences in patient characteristics need to be adjusted for. 
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When RCTs are given first priority in the assessment of effects, internal validity is prioritised over external 
validity or, in other words, efficacy is prioritised over effectiveness. Since the economic evaluation 
concentrates on cost-effectiveness, cf. chapter II, the rationale of a hierarchy that prioritises efficacy over 
effectiveness is not clear. 
 
If costing is included in the design of a RCT, it is possible to carry out a prospective, and potentially bottom-
up cost assessment, which can be more detailed compared to a retrospective cost computation. Often 
however, the RCT-based cost assessment is based on top-down assessments, accounting figures or ‘piggy-
backed’ cost collections85, neither of which are superior to a register-based cost computation. Using cost 
assessment alongside RCTs (piggy-back) may generate results that deviate from a real-world situation. If 
trial patients are ‘too healthy’, their health care costs consequently are ‘too small’. On the other hand, the 
cost of the trial set-up, and the cost of the redundant trial resources if too few patients fulfil participation 
criteria or agree to participate, could inflate cost figures. In the case of redundant trial resources, the 
analysis may be based on the assumption of efficient use of resources and not observations of real costs, 
rendering cost conclusions uncertain86. Further, trials are often conducted in large university hospitals, 
where the cost structure may be different from smaller hospitals44. 
 
Other issues that potentially render the RCT imperfect for use in economic evaluation comprise the choice 
of ‘usual care’ and a sample size that could cause statistical power problems43. 
 
External validity has retained focus as the most important problem with RCTs; and can be solved e.g. 
through use of  pragmatic trials20;79. Another problem has not been discussed as thoroughly. Since trials are 
often conducted within a short time frame, long-term effects (and costs) are disregarded. Effects can be 
divided into intermediate and final outcomes; intermediate outcomes are e.g. readmissions within 6 
months or a year, while the final outcome typically is mortality. Due to the limited time frame of the RCT, 
the focus remains on the short-term outcomes43. There are no features of the RCT that prevent long-term 
analysis; however there may be a pressure from decision makers, pharmaceutical companies and others, 
for the trial to render results. Therefore funding for the trial may only be obtainable for short time periods. 
Due to these time restrictions and perhaps also statistical power problems, as trial populations are often 
small, many trials focus on intermediate outcomes41. The analysis time frame is sometimes extended 
beyond the short study time frame in order to assess final outcomes. To this end modelling or extrapolation 
is used. This is described later in this chapter. 
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Since long-term consequences are important for both health care and health promotion interventions43, 
the short analysis time frame of many RCTs is potentially a problem.  
 
There remains a wide scope for use of RCT-based evidence, however in many cases this evidence is not 
superior to other types of evidence, either due to RCTs being small and restrictive, or in the presence of 
good quality register-based data71;87. Thus, for economic evaluations, choosing RCT-data based on a 
hierarchy may not always be the optimal strategy. 
 
Register-based data 
The term ‘register-based data’ covers a variety of data sources, including cohort studies, research registers, 
clinical databases, administrative registers and accounting databases. Most often individuals are selected 
for inclusion in the register on the basis of their residence, condition, treatment hospital or similar. 
Registers that are designed for research purposes, such as cohorts, contain a number of variables that 
potentially could confound results. Hence cohorts are designed so as to account for some central 
weaknesses of registers and therefore often provide quite powerful data sources for research. 
 
Administrative registers are perhaps in the opposite end of the spectrum as they are designed with a 
different purpose and may not contain the information sufficient to adjust for all confounders, nor for 
collection of all relevant cost data44. In between cohorts and administrative registers are data sources such 
as patient registers and clinical databases. For use in cost-effectiveness analysis, registers should ideally 
contain both information on the disease and the costs involved43.  
 
Validity 
Studies of health care or health promotion interventions based on register-data are regarded as inferior to 
RCT-based studies mainly for reasons of internal validity. A register-based study typically compares the 
effect of a new treatment or intervention offered to one patient group, with the effect of standard 
treatment offered to another patient group. In some studies, standard treatment is offered up to a specific 
point in time, after which the treatment regime changes, and the new treatment is offered universally. 
Thus the register-based study compares the patient group at one point in time to a comparable group at 
another point in time (e.g. one year later). Other register-based studies compare the group of patients in 
one hospital to a group of patients in another hospital, while yet other studies compare two or more 
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different patient groups in one clinic. A common feature for all types of register-based studies is that 
patient groups may not be entirely comparable. 
 
Those register-based studies that compare treatments at different points in time may suffer from a weak 
comparability of treatments, as everything else may not be equal between the two points in time. Also, it 
should be considered that patient characteristics may change when the treatment regime changes. E.g., a 
new supposedly superior treatment is offered to patients for whom the standard treatment was considered 
unfeasible.  
 
Similarly, patient characteristics could differ between two hospitals taking part in a register-based study. 
When the two patient groups are treated alongside each other in one clinic, the indications between 
treatments may be different.  
 
Thus, compared to RCTs, analyses based on register data contain more noise and therefore the internal 
validity is potentially weak. On the other hand, external validity appears to be quite good in register-based 
studies88, as results can be more easily generalised, and hence applicable in real-world settings. For 
register-based studies, it should be carefully considered if all or most possible confounders can be adjusted 
for. Most register-based data contain information on age, gender, socio-economic status and other 
features that can be used for adjustment. Adjustment is necessary in order to isolate treatment effect from 
the effect of covariates. In cohorts, or register data merged with survey data89, information such as HRQoL 
and self-reported lifestyle is often recorded. However if such items are not recorded in the register, 
potential differences between patient groups cannot be adjusted for. Co-morbidity constitutes a related 
problem. If the patients receiving one treatment are more ill (e.g. they may have a higher prevalence of 
diabetes) than the patients receiving the other treatment, this difference could flaw the analysis and 
ultimately the results. Some registers comprise information on treatment for other diseases and hence co-
morbidity, allowing for appropriate adjustment. For methods of adjustment, see below. 
 
Findings on effectiveness are also easier generalised in the register-based study than in the RCT, although 
some reservations may apply. E.g., if one hospital is applying the new treatment and another is applying 
usual care, results from one hospital may not apply universally to the other hospital, as there may be 
demographic differences between hospitals or differences in level of expertise or other differences that 
possibly affect the treatment outcome.  
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For cost measurement, register-based analysis may in fact be superior to RCTs. A register-based cost 
assessment can relatively easy be generalised to everyday clinical life, as the reservations for generalising of 
the RCT do not apply90. The applicability of register-based data renders these data more valid for evaluation 
of cost-effectiveness in real-world settings, than data from RCTs that do not resemble the real world to the 
same extent. 
 
Time frame 
A strong advantage of retrospective register-based studies is that they, more often than RCTs, allow for 
analysis of long-term consequences as a current outcome of an exposure in the past88. In addition, duration 
analysis of survival or labour market affiliation can be conducted over long periods of time. In paper 2, we 
conducted a duration analysis of labour market affiliation amongst CHD patients for up to 23 years based 
on register data13.  
 
For analysis of most health promotion interventions, the relatively long time span between the intervention 
and the final outcome provides an additional challenge. E.g. the final outcome of a smoking cessation 
programme will only materialise much later in life, when the participants live longer and experience less 
disease. Therefore, economic evaluation of health promotion programmes requires either a register with 
long follow-up time or simulation of the long-term effects. Paper 1 provides an example of a cohort study 
where the impact of lifestyle interventions are analysed16. For health care interventions as well, the longer 
time horizon of register-based studies allows for analysis of final outcomes as opposed to intermediate 
outcomes. The time horizon of costs is very important as well. As demonstrated in paper 3, expanding the 
time frame can alter results due to the inclusion of longer-term costs in the analysis. These long-term costs 
are often more readily available in register-based studies, in particular retrospective studies, than in RCT 
studies.  
 
The efficacy-applicability trade-off 
Whether register-based data are in fact inferior to RCT data, as suggested by various hierarchies71, depends 
on the relative importance of external versus internal validity, or applicability versus efficacy79;82. The 
applicability-efficacy trade-off is central for the choice of data sources in economic evaluation. While it can 
be argued that RCTs are necessary in the process of establishing the efficacy of an intervention82, 
applicability may be much more important when assessing cost-effectiveness. Economic evaluations are 
usually used to make decisions on whether to implement interventions in real clinical life, and therefore 
applicability of analysis results is very central. In studies where the effect difference between interventions 
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is negligible, there is still a rationale for CEA. In the event of an intervention displaying a significant effect in 
a RCT, but having null effect in a register study, decision makers should take into account that application in 
real life could produce a null effect as well. 
 
In Denmark, there exists a variety of registers that can be applied for CEA. In papers 1 and 2, we used the 
DANCOS cohort, comprised of national health interview survey data merged with comprehensive register 
data on health care utilisation, labour market behaviour, socio-demographic characteristics etc., allowing 
for analyses that include both self-reported health and lifestyle and register-based information. The ability 
to adjust for almost all possible confounders renders this cohort a powerful data source for analysis of costs 
and effects. In paper 3 we applied a patient register with detailed clinical information but also including 
register-based demographic characteristics and self-reported lifestyle parameters. These data sources 
provided information of sufficient magnitude and quality for the performed analyses. Paper 3 is an 
economic evaluation of two interventions used in real clinical life. We were able to adjust for several 
confounders in order to take into account that the two patient groups had different characteristics at 
baseline.  
 
In summary, the choice of data for economic evaluations should be based on the efficacy-applicability 
trade-off rather than a hierarchy, as register-based data in some cases may be superior to RCT data, namely 
in those cases where applicability is considered more important than making conclusions on efficacy. 
 
Using register-based studies in economic evaluations 
Analysis of register-based data can take place as either time series, cross-sectional or as panel data analysis. 
Time series analysis focus on the development of indicators over time, while a cross-sectional analysis focus 
on the differences between individuals at a certain point in time. Panel data analysis combines the two and 
analyses differences between individuals and between periods simultaneously. A panel data set will usually 
contain a number of variables per individual in more than one period of time. A cohort constitutes a good 
example of panel data; indeed most register-based analysis in the field of health care takes the form of 
panel data analysis. While one-period cross-sectional data could be applied in economic evaluations, time 
series data are of rather limited relevance in this field. 
 
The cross-sectional or panel data include a number of variables on health care utilisation that are useful for 
cost assessments. E.g. hospital admissions coded with the relevant DRG-tariff, or specialist services coded 
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with applicable charges. Further, the data comprise variables that can be used for effect measurement, 
such as health status, HRQoL and mortality. And finally, the panel data contain variables that are possible 
confounders and should be used in adjustment for confounders. Examples of such variables are age, 
gender, socio-economic variables, lifestyle, and residence.  
 
As described in chapter II, the economic evaluation compares costs and effects of two or more treatment 
regimes. In the register-based economic evaluation, patients or participants are divided into groups 
according to their treatment regime. The analysis identifies cost differences and effect differences between 
groups, adjusting for appropriate covariates. 
 
The register-based analysis is often a regression analysis. In the linear (ordinary least squares) regression 
model, costs or effects are expressed as a function of treatment group and appropriate covariates. The 
model includes an error term and is subject to a number of assumptions. Firstly, the relation between 
dependent and independent variables should be linear, and secondly the error term is subject to a number 
of restrictions, e.g. it should be normally distributed and must not display heteroskedasticity (when error 
terms have different variances91). For cost data in particular, the assumption of normally distributed error 
terms is often violated. In order to apply the linear regression model, data are prepared by means of 
logistic transformation. Results are retransformed by means of smearing techniques92. The advantage of 
the linear regression model in economic evaluation is that the group or treatment regime parameter 
presents a quantification of the cost or effect difference between groups. In paper 1 we applied linear 
regression with logistic transformation for computing the health care costs of heart disease and risk 
behaviour. 
 
Other regression methods comprise logistic regression and generalised linear modelling. For survival or 
duration analysis, such as the one performed in paper 2, Cox regression is most often used. The result of 
the Cox regression is a hazard ratio, expressing the difference in risks of a certain outcome between groups. 
The Cox regression assumes proportional hazards, meaning that the relationship between the risks of the 
compared groups should be constant over time. If this assumption is violated, other models should be 
applied93. In paper 3, the proportionality assumption was violated and a Weibull accelerated failure time 
model was therefore used to identify the effect difference between groups. 
 
A key issue in the register-based economic evaluation is the adjustment for relevant covariates. In this 
process, firstly possible confounders need to be identified. A number of covariates, such as age, gender and 
Short and long-term consequences of coronary heart disease 
 
 
 
Page 44 
 
socio-economic parameters, are almost always included in the analysis. For other variables, a non-
parametric test can verify whether there is a detectable and significant difference between groups. Most 
often, the impact on results of potential confounding variables is tested by including and excluding these 
variables in the model.  
 
When the number of covariates that potentially qualify for adjustment is high, the effect of each covariate 
becomes difficult to identify in the regression model as the explanatory power becomes insufficient. A 
solution to this problem is to summarise information on all relevant covariates in the propensity score94;95 
which is a compound measure consisting of all covariates, generally transformed into a scalar and grouped 
into quintiles. The regression model becomes quite simple as the explanatory variables are reduced to two: 
treatment group assignment and propensity score quintile.  
 
Thus, register data in the form of panel data and cross-sectional data provide a strong basis for economic 
evaluation as they contain not only a variety of applicable analysis variables but also vast opportunities of 
adjustment for those covariates that could potentially bias results. 
 
Meta-analysis and decision modelling 
Meta-analyses and decision models represent ways of analysing costs and effects of health care 
interventions in the absence of applicable RCT or register data for the desirable time frame. The meta-
analysis usually compiles RCTs within a given area and draw conclusions based on the compiled data. The 
trials put together represent a larger analysis population and lesser uncertainty.  
 
Decision models can acquire their data from RCTs or register analyses or both. The model is built around 
these data while assumptions about mortality and similar features are based on population data. They 
often take the form of a Markov model, in which patients either remain in a given health state, or move 
into another health state. Health states can be, e.g., disease-free, recurring disease, or dead. The 
probabilities of moving from one state to another, the transition probabilities, are based on data from RCTs 
or registers. The Markov model can simulate any number of years; often a cohort is followed for lifetime. 
RCTs will normally not provide sufficient data for the long-term analysis, as their time frame is much 
shorter. For the analysis of lifetime effects, assumptions are made regarding the changes in transition 
probabilities over time. E.g., when a CHD patient has a stent implantation during angioplasty, little is known 
of the long-term effects of the implantation or the health care costs over a longer period of time. 
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For analysis of costs over the longer term, decision models also derive their transition probabilities from 
available data or from the literature. Costs relate to the health states described by the Markov model. It is 
assumed that the cost of a repeat surgery is the same regardless whether it takes place six months or six 
years after the index surgery. Unrelated health care costs may however change over time, in most 
simulation studies these are derived from the literature.  
 
As meta-analyses and simulation models are based on existing RCT and register-based data, problems of 
internal and external validity, statistical power problems and similar are inherited from the original data. 
Observations regarding strengths and weaknesses of RCTs and register-data thus also apply to their 
secondary use. A good meta-analysis is, however, in some hierarchies of evidence considered superior to 
the RCT, as the compilation of RCT data accounts for some of the problems associated with single RCTs71. 
 
However, use of decision models can extend the time frame of the economic evaluation from the short to 
the long term, thus accounting for the reservation that most RCTs, and some other studies, apply a time 
frame that is too short to capture all relevant costs and effects. The uncertainty relating to the 
development of costs and effects beyond the trial period should however be analysed43.  
 
Summary 
In this chapter, I have assessed three categories of data for economic evaluations: RCTs, register-data and 
meta-analysis or decision models. I have argued that register-based data may be of greater value than trial 
data in the assessment of costs, and that the prioritisation of data for effect measurement depends on 
one’s position on the efficacy-applicability trade-off rather than on a hierarchy.  
 
When analysing costs and effects within a sufficient time frame, register-based data may be more 
appropriate than RCTs due to a longer time horizon of costs. Use of decision modelling can expand the 
analysis time horizon thus enabling the analysis to capture all relevant costs and effects. 
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IV.  Literature review  
 
 
As outlined in chapter III, data for economic evaluations originates from different sources: notably RCTs and 
register-based data. Also, the approach, perspective and time frame of the economic evaluation differ 
between studies. While there are some attempts at establishing a reference case for economic evaluations, 
notably by the US Panel45;56 but also by some national agencies in Europe63-65, these have not been followed 
universally. In this chapter, I assess register-based, RCT-based and model-based economic evaluations in 
recent literature on CHD, focusing on their perspective and time frame and the data sources applied in the 
analyses. Finally I will relate the findings of the review to selected items of the US Panel reference case. 
 
The review was limited to health care interventions aimed at CHD, and the focus of the review was firstly 
the perspective stated by the evaluation study, being societal, health care sector or other, secondly, the 
time frame of the study, and, finally, the methods used for gathering data for the evaluation, being RCT, 
register-based data, or modelling of RCT-data or register-data.  
 
Search strategy 
The databases Pubmed, Cochrane, the HTA database and the NHS economic evaluation database were 
searched for combinations of the following terms: ‘cost-effectiveness’ or ‘cost-utility’ in combination with 
‘coronary heart disease’ or ‘ischemic heart disease’ or ‘angina’. Studies had to be published from January 
2005 to March 2009 and had to be in English. Further, only studies with explicit and replicable cost 
estimates were included; and the analysis should relate to interventions that directly involved patients. In 
other words, economic evaluations of laboratory techniques or organisational changes were excluded.  
 
Figure 1 displays the search process and the definition of eligible studies.  
 
  
Short and long-term consequences of coronary heart disease 
 
 
 
Page 48 
 
Figure 1: Overview of inclusion procedure 
 
 
 
From the initial search, 149 studies were identified. Out of these, 61 fulfilled the eligibility criteria. 23 were 
based on RCTs, 9 on register-based data, 18 studies were decision modelling studies which were based on 
RCTs (n=8), on register-based data (n=5) or on meta-analyses which could comprise both RCT and register-
data (n=7). The remainder were meta-analyses based on RCTs (n=5) and on register-data and RCTs (n=4). 
Meta-analyses and decision modelling studies were categorised according to the type of data they were 
based on. Therefore, the 61 studies were categorised as follows: RCTs, register studies and studies based 
on combined data sources. Each category was subdivided according to use of a decision model (Markov 
model or similar) or not. The 61 eligible studies are displayed in table 1: 
 
149 studies identified in search
140 studies
103 studies
83 studies
72 studies
A total of 61 studies were assessed
11 studies without explicit cost computation
11 studies were not patient related
20 studies did not pertain to coronary heart disease
37 studies were reviews 
9 studies were abstracts or in non-English language
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Table 1: Cost-effectiveness studies of coronary heart disease interventions – categories and cost 
perspectives 
Study type and references Number of 
studies 
Health care 
sector 
perspective 
Third party payer 
perspective 
Societal 
perspective 
Randomised controlled trials 
96-
131
 
36 29 3 4 
Register based studies 
132-145
 14 9 5 0 
Studies using a combination of 
register and RCT 
146-156
 
11 6 2 3 
Total 61 44 10 7 
 
 
Perspective 
In this review, studies were categorised according to their own perception of perspective. Perspectives 
were divided into the health care sector perspective, e.g. the NHS in UK studies63, the third party payer 
perspective (e.g. a German ‘Krankenkasse’ or an American insurance company) and the societal 
perspective. The latter appears to be defined differently in different studies.  
 
As described in chapter II, the US Panel argued that the cost computation of an economic evaluation should 
apply a societal perspective on costs45;56. From Table 1 it appears that application of a societal perspective 
was stated in 7 of the 61 reviewed studies. Amongst the seven studies, there appears to be some 
discrepancy regarding the definition of the societal perspective. In some studies the societal costs were 
identical to health care costs103;109;147, one study regarded the societal perspective to be health care costs 
plus patient time costs98 while three studies included productivity costs and to some extent also net 
consumption in added life years to their cost estimate101;146;153.  
 
These three studies, all Swedish, mentioned the Swedish guidelines for economic evaluations in health 
technology assessment and its recommendations to include also ‘indirect costs’. The Berg et al paper153 
analysed the cost-effectiveness of Clopidogrel (a pharmaceutical) in the treatment of myocardial infarction, 
using a decision model based on RCT data from three countries: Sweden, France and Germany. As the 
Swedish guidelines differ from the French and German guidelines, total costs were computed differently for 
the three countries. Therefore, the broad societal perspective was only applied for the Swedish data. Berg 
et al stated that indirect costs comprise productivity costs only. They reported the direct costs of 
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myocardial infarction in Sweden to be €5,700 and indirect costs more than €12,000, or more than double 
the direct costs. With a reference to Meltzer (1997)53, they also included survivor costs in a sensitivity 
analysis. The result of this analysis was not reported, although it was mentioned in the text that including 
survivor costs would entail a cost saving for patients aged less than 64 and additional costs for older 
patients.  
 
The Lindgren et al (2005) study also pertained to Clopidogrel treatment, here in combination with aspirin 
and aimed at angioplasty patients146. The cost assessment of this study also applied a societal perspective. 
As for the Berg et al study, indirect (productivity) costs were included (and excluded) in a sensitivity 
analysis, and survivor costs were included in another sensitivity analysis. When survivor costs were 
included, the ICER increased almost threefold. Contrary to the Berg et al study, Lindgren et al found indirect 
cost of a much smaller magnitude, 10-20 percent of direct medical costs. It seems that there is a 
discrepancy between the findings in these two studies with regard to the magnitude of indirect costs. As 
the analysed treatments of the studies were rather similar and there were no major age differences 
between patient populations, this difference must be related to computation methods.  
 
Lindgren et al (2007) focused on the cost-effectiveness of statin treatment in the secondary prevention of 
coronary heart disease. More specifically, they compared high-dose Atorvastatin with regular dose 
Simvastatin in four Scandinavian countries. The study applied trial data in a lifetime Markov model101. The 
authors included ‘indirect costs’ or work absence, and estimated the value of indirect costs as equal to the 
average wage plus the employer’s contribution. The latter component was not specified but may be 
interpreted as profit. Including a profit term implicitly assumes that the analysed labour market is not in 
equilibrium; however the inclusion of the profit term was not discussed in the study. The total indirect costs 
amounted to about €1,150 per week of work lost in Denmark and less than half of that amount in Finland. 
As the study analysed a secondary prevention intervention, there was a productivity gain related to the 
intervention, and therefore the total costs were reduced as a result of including productivity costs, more so 
in Denmark than in Finland. 
 
Although the same first author in a previous study146 estimated survivor costs of the analysed intervention, 
this option was not included in this study, and the societal perspective was limited to inclusion of 
productivity gains. 
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The societal perspective was stated in four other studies. Chan et al (2007) made a reference to the US 
Panel in their approach to cost calculation, however only direct medical costs appeared from their overview 
of cost components109. Similarly, Schleinitz and Heidenreich (2005), in their assessment of different 
combinations of pharmaceuticals in the treatment of myocardial infarction103, as well as Mahoney et al 
(2005) in their analysis of Clopidogrel147, stated the societal view but seemingly did not include cost 
components outside the health care sector. Hence, for these studies the societal perspective was equal to 
the health care sector perspective. 
 
Hay and Sterling (2005) seems to be the only reviewed study to have adopted the recommended 
perspective of the US Panel reference case, as their cost figure included patient time costs spent in 
treatment98. They also compared their finding to the societal threshold of costs per QALY. Hay and Sterling 
analysed the cost-effectiveness of a preventive measure, treatment of low HDL-cholesterol, as a primary 
prevention of coronary heart disease.  
 
Prevention of a potentially fatal, serious disease such as coronary heart disease is likely to render a 
significant gain in life years and therefore also incurs important changes in productivity. According to the 
US Panel, these changes are included in the QALY45;56, however this does not apply to the resulting 
opportunity costs for others. Primary prevention of coronary heart disease through cholesterol 
management is an example of an intervention where inclusion of survivor costs would have had a major 
impact on results. 
 
The majority of the reviewed studies were confined to the health care sector, and sometimes even 
narrower, regarding only drug costs110;138 or programme costs123;137. The study by Finkelstein and colleagues 
(2006) analysed a lifestyle intervention aimed at preventing coronary heart disease137. Therefore, their 
choice of applying a programme perspective is not obvious. Large cost savings, in the health care sector as 
well as for society as a whole, could be obtained through a successful prevention measure. Including only 
programme costs renders the prevention programme less cost-effective than would have been the case, 
had the authors applied a broader cost perspective.  
 
Most studies that applied the health care sector perspective included future unrelated health care costs, 
although only for the study period105;106;118-120. British studies such as Campbell et al (2005) and Briggs et al 
(2007) applied the perspective of the NHS, which includes also unrelated health care costs107;108. This, 
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however, was not always the case. A few studies stated the health care sector perspective but did not 
include unrelated medical costs116;155.  
 
Economic evaluations of health care interventions with a limited time frame did not consider health care 
costs beyond the specified time frame. The time frame of studies is also important for the findings of the 
economic evaluation. 
 
Time frame of studies 
Data collection in an economic evaluation takes place within the study time frame. Application of a decision 
model extrapolates the findings of the study period and thus expands the analysis time frame beyond the 
study time frame. The focus here is the analysis time frame. A reservation should be made; however, 
regarding extrapolation of findings from a very short study time frame. As described in chapter II, the US 
Panel recommended that an economic evaluation applied a time frame being sufficient to capture all 
relevant costs and effects45. This recommendation relates to the analysis time frame, while the study time 
frame should be sufficient as to render results to be used for the extrapolation. In studies without 
extrapolation, the analysis time frame is identical to the study time frame. 
 
For chronic diseases a sufficient time frame is several years or lifetime. Of the 61 reviewed studies, about a 
third applied the lifetime perspective on costs and effects. Decision model studies were well represented in 
this category. The extrapolation in the decision model allows for assumptions beyond a RCT or register time 
frame. In particular for RCTs with the popular time horizon of one year or less, extrapolation provides a 
means of analysing the long-term perspective. Almost half of the reviewed studies are RCTs without 
extrapolation. Compared to the other half of the reviewed studies they had a rather short time horizon. 75 
percent of RCTs without extrapolation had a time frame of less than five years. In table 2 the studies are 
divided according to analysis time frame, type of data source and whether findings had been extrapolated 
or not. 
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Table 2: Analysis time frame of economic evaluation studies 
Study type and references Less than a 
year 
1 year More than 
1 year and 
less than 5 
years 
5-50 
years 
Lifetime 
Randomised controlled trials 
 Extrapolation
96-103
(N=8) 0 0 1 0 7 
 No extrapolation
104-131
(N=28) 3  9 9  4  3  
Register based studies 
 Extrapolation
132-136
(N=5) 0 0 0 2 3 
 No extrapolation
137-145
(N=9) 1 2 1 5 0 
Studies using a combination of register and RCT 
 Extrapolation
146-152
(N=7) 0 0 0 1 6 
 No extrapolation
153-156
(N=4) 0 0 0 2 2 
Total all studies 4 (7%) 11 (18%) 11 (18%) 14 (23%) 21 (34%) 
 
Only a few studies applied the limited time frame of less than a year112;118;131;138. The study by Zebis et al 
(2008) analysed the cost-effectiveness of Amiodarone, a pharmaceutical given to coronary bypass patients 
immediately after surgery in order to prevent atrial fibrillation as a post-operative complication131. The 
effect measure was cases of atrial fibrillation avoided, and since this only occurs during admission, the 
authors chose to include only costs during admission. Thus, the authors ignored not only downstream 
health care costs but also the impact on survival and HRQoL of avoided atrial fibrillation during admission.  
 
The study by Fischell et al (2006) focused on the use of Eptifibatide – a pharmaceutical that prevents 
complications following angioplasty138. The authors chose a time frame of one month, thus disregarding 
downstream health care cost savings beyond one month, and potential QALY effects of avoided 
complications. 
 
Lewin et al (2009) analysed the cost-effectiveness of a rehabilitation scheme for patients receiving an ICD, 
and included physical and mental health as well as hospital admissions as effect measures118. An ICD is 
implanted for more than six months and it is therefore somewhat surprising that the authors have chosen 
the short time frame of six months for their assessment. 
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Several studies applied the time frame of one year106;108;110;111;116;121;122;127;128;137;142. Many RCT studies used 
the trial period as the study period for costs and effects and failed to discuss the possibility of future costs 
(including downstream medical costs) or effects occurring beyond the trial period. However, also some 
register based studies applied a limited time frame. The Finkelstein et al study137, which was also discussed 
above, was a register-based analysis of a prevention programme, which seemingly disregarded effects and 
costs, including savings, in other sectors as well as in the longer term. It appears that the particular 
prevention programme did not receive a fair treatment. Effects of a prevention programme, including 
health care costs savings (as well as savings in other sectors), could easily materialize several years from the 
intervention.  
 
Illustrative of the problems relating to the short time frame are the findings by Briffa et al (2005)106 in their 
evaluation of a cardiac rehabilitation programme, which constitutes secondary prevention and therefore is 
likely to have an impact on the longer term. The study was based on a trial and analysed costs and effects 
for one year. The authors found an ICER of 42,535 Australian dollars (approximately €25,000) for cardiac 
rehabilitation compared to conventional care. In a sensitivity analysis, the time frame was extended to 
three years, which rendered an ICER of 27,030 Australian dollars (€16,000). This finding underlines the 
significance of the selected time frame. 
 
The Ohsfeldt et al (2006) study focused on statin treatment in primary practice142 but only followed 
patients for one year. As statins are used for prevention of coronary heart disease, the reservation 
regarding time frame of analysis of prevention programmes applies to this study as well. An example of a 
cost-effectiveness study of a prevention measure which applies a lifetime horizon is Quist-Paulsen et al 
(2006)123 that assessed smoking cessation programmes as a means of preventing coronary heart disease. 
The full impact of smoking cessation on costs and effects was seen in the lifetime perspective only. 
 
To summarise, health care interventions can have long-term consequences as well as future costs or cost 
savings that are disregarded in economic evaluations with a too short time frame. Studies focusing on 
intermediate outcomes such as the prevention of post-operative complications131;138, ignore the impact of 
the intermediate outcome on final outcomes such as QALYs. On the contrary, preventive measures usually 
incur costs on the short-term and costs and savings on the longer term. Also, the effect of a prevention 
measure is rarely limited to the short-term. Therefore, when analysing both prevention measures and 
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health care interventions in general, the time frame as well as the perspective should be chosen carefully, 
taking all possible costs and effects into consideration. 
 
Data sources 
The economic evaluation needs to be based on some data on costs and effects of interventions. These data 
could be drawn from RCTs or registers, and findings could be extrapolated in a decision model in order to 
expand the analysis time frame. The US Panel drew no strong conclusion on the desirability of RCTs versus 
register-based data in their described reference case41. Both data sources for economic evaluation have 
advantages and disadvantages as discussed in chapter III. 
 
Here, the data sources for economic evaluation were grouped into three categories, crudely disregarding 
the vast differences within each category. For RCTs, some are small and include patients that may not be 
representative of the relevant patient population106;108;112;114, while others are meta-analyses104;105;109;115;117 
or piggy-backed on large trials107;110;111;113;116;119;121. It is not possible to draw any conclusions about external 
validity overall for this category.  
 
In addition to the external validity of effects, cost-effectiveness studies based on trial data may not reflect 
the costs that could occur in a real, clinical setting. Indeed, this issue was addressed by Lindgren et al (2007) 
in a trial-based cost-effectiveness analysis of statins in secondary prevention: 
‘As we used trial data to estimate the cost associated with each MI and revascularization, it is possible that 
some potentially important cost-drivers has been omitted.’ 
Lindgren et al (2007), p. 1451101 
 
An example of this omission is discharge to nursing homes, which is rather costly. If trial participants were 
healthier and hence less costly than patients in the real world, the cost-effectiveness results could change 
markedly if based on real world data. 
 
Similarly, register-based studies assessed the internal validity challenge very differently. Most register 
studies were major cohorts137;139-141;143-145, and thus comprised a number of variables for adjustment, while 
at least one study was perhaps too small to comprise sufficient information on possible confounders138.  
 
The study by Ohsfeldt and colleagues (2006)142 represented an example of a register-based study which 
involved a major effort to deal with the issue of internal validity. The authors have analysed the 
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effectiveness and cost-effectiveness of different statins for prevention of coronary heart disease in routine 
clinical practice. They selected a cohort of patients by a set of eligibility criteria and adjusted results for 
several parameters collected at entry. When parameters from a comprehensive list of possible confounders 
are collected and subsequently adjusted for, the presence of another confounder that would markedly 
change results if adjusted for, becomes highly unlikely. 
 
The validity discussion seems to have concentrated on internal and external validity of effects, while the 
validity of costs has been disregarded to some extent. In the register-based studies, where cost information 
was derived from the register or from administrative data from the ‘real world’, cost figures will normally 
reflect or be close to the true costs of the intervention and its consequences. As mentioned by Lindgren et 
al (2007)101, this may not be the case for RCT-based cost computations. 
 
To summarise, the issue of external validity is handled best by studies based on observational data, 
registers or cohorts recruited from the ‘real clinical world’. The challenge of these studies relates to the 
internal validity, or the minimisation of statistical noise. Most of the register-based studies reviewed here 
approach this issue carefully by accounting for a comprehensive set of possible confounders.  
 
Is there a case for the reference case? 
The impression of the above review of economic evaluations within the field of prevention and treatment 
of coronary heart disease is a very heterogeneous approach to perspective, time frame and use of data 
sources. Most studies applied the health care sector perspective, or similar, perhaps to some extent based 
on feasibility considerations. The heterogeneity in approach is not limited to the field of CHD, a similar 
image appears from other fields of health care research, e.g. in the field of aortic aneurysms, where cost-
effectiveness analyses display different time frames and use of data sources157.  
 
The recommended reference case of the US Panel (described in Chapter II) differed from most of the 
reviewed studies56, at least on their suggested perspective. The US Panel suggested application of the 
societal perspective, which, in their view, included only patient time costs outside the health care sector. 
The societal perspective was taken in seven of the reviewed studies. Amongst these, the definition of the 
societal perspective seemed to vary somewhat. One study included time costs in addition to health costs98, 
as suggested by the US Panel, while three studies101;146;153 adopted the societal perspective which is 
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recommended by the Danish and Swedish health technology assessment guidelines64;65. Three 
studies103;109;147 only included health care costs in their societal perspective. 
 
The US Panel also suggested analysis over a sufficient time horizon in order to capture relevant costs and 
effects. A sufficient time horizon could be patient lifetime, which may only be feasible when a decision 
model is applied on the collected data. Indeed, most of the decision models reviewed took the lifetime 
perspective, while most studies without modelling applied a shorter time frame. Almost a quarter of the 
reviewed studies applied a time frame of five years or more, which may be sufficient. With regard to its 
recommended time frame, the reference case is adhered to much more extensively than was the case for 
the recommended societal perspective. 
 
For data sources, the US Panel was more ambiguous in their recommendations, indeed they recommended 
that evidence for effectiveness may be obtained not only from RCTs and register data but also from 
uncontrolled experiments and expert opinions. In addition, modelling and meta-analysis can be applied 
when data or duration of data is insufficient41. The Panel however retained good quality RCTs as their first 
choice for data for cost-effectiveness studies in health care. 
 
While there may still be a rationale for a reference case for economic evaluations of health care 
interventions, the one suggested by the US Panel has not gained sufficient use to be a candidate. An 
international reference case is perhaps not very relevant, as decisions on health care interventions are 
nationally based and comparability of economic evaluations at the national level therefore should be 
prioritised. On the other hand, comparability of results with existing literature is an integral part of most 
evaluations and therefore some homogeneity is desirable. On the national level, recommendations exist for 
economic evaluations for health technology assessment in some countries. In the UK, NICE has issued a set 
of guidelines that are generally accepted for use in UK cost-effectiveness analyses63. NICE recommends use 
of the NHS perspective for cost assessments, a clear deviation from the US Panel, and also from the 
rationale of the CEA that suggests a societal perspective, cf. chapter II. In Sweden, the Pharmaceutical 
Benefit Board also issued a set of guidelines differing from the US Panel in the opposite direction. Thus, the 
Swedish and Danish guidelines argue in favour of including also ‘indirect costs’ related to the intervention, 
productivity costs and gains following from the impact on life expectancy64;65.  
 
A modified reference case for economic evaluations of health care interventions could include: a sufficient 
time frame, a societal perspective, and data from good comprehensive data sources. This case has been 
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argued above, and is summarised as follows: the time frame should allow for all relevant costs and effects 
to be taken into account, in particular but not only for prevention interventions. The perspective should be 
societal in order to result in efficient resource allocations70 and include survivor costs in the 
acknowledgment that increased life expectancy incurs opportunity costs on others49. Finally, in the words 
of Drummond et al (1997)20, the economic evaluation should be based on the best available data, and not 
necessarily the data originating from the top of the hierarchy77. In fact, as it was argued in chapter III, for 
cost assessments, register-based data may be superior to RCTs, while the choice of data for effect 
measurement should be based on the efficacy-applicability trade-off. 
 
The next chapter carries these points forward to a brief overview of the methods and data sources applied 
in this PhD. 
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V.  Costs and consequences of coronary heart 
disease: methods and data sources 
 
 
In chapters II and IV, existing recommendations for economic evaluations were introduced and in particular 
the US Panel reference case was described and discussed. The Panel issued several recommendations, and 
a few of these with specific relevance for this PhD are further discussed below. According to the US Panel, 
adherence to the reference case suggests that an economic evaluation45: 
 Applies a time frame sufficient to capture all relevant costs and effects 
 Analyse cost-effectiveness from a societal perspective albeit excluding productivity costs 
 Use available data sources with good quality with RCTs as the first choice41 
While only one of the four papers that make up this PhD is an actual economic evaluation, all four papers 
are associated with economic evaluation in one way or another. The four papers are related to the above 
three elements of the US Panel reference case below. 
 
Time frame 
Coronary heart disease is a chronic, serious disease with a variety of long-term consequences. Therefore, 
assessment of costs and consequences should take the longer term into account. The recommendation by 
the US Panel, that the time frame should be sufficient to capture all relevant costs and effects is very 
important. 
 
Paper 1 focuses on the lifetime health care costs of a new event of CHD and the additional costs of an 
unhealthy lifestyle. We only analysed costs however with the explicit aim of providing cost data for 
economic evaluation of preventive measures.  
 
In paper 2, we analysed long-term labour market consequences of CHD. The register-based duration 
analysis allowed for assessment of consequences in up to 23 years after the index event. For some 
individuals the time frame was somewhat shorter, however the analysed time span was sufficient in order 
to draw conclusions on long-term consequences of CHD. 
 
The economic evaluation in paper 3 concerned drug-eluting stents in coronary angioplasty. The study 
applied a time frame longer than most studies of the same topic. We had access to register-based data for 
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five years, and thus used a time frame fivefold that of the bulk of studies based on RCTs in the same field. 
The long time frame added important information to the study, as both costs and effects for the two 
compared treatments developed differently over time. 
 
Paper 4 does not relate to coronary heart disease per se but does provide figures for future costs in an 
analysis with lifetime perspective. The analysis in paper 4 is based on the acknowledgment that future costs 
or survivor costs do play a role in cost-effectiveness measurement. The issue of survivor costs is examined 
in chapter II. 
 
Perspective 
Papers 1 and 3 apply the health care sector perspective, like most economic evaluations in the field. 
However, costs of heart disease and risk behaviour do occur outside the health care sector. Notably, paper 
2 demonstrated that an event of coronary heart disease has important implications in the labour market.  
 
It seems that there are two reasons why most economic evaluations choose to differ from the 
recommended societal perspective, one reason being that costs outside the health care sector are difficult 
to assess because there are measurement and valuation problems associated with these costs. 
 
Another reason relates to costs from the societal perspective being difficult to define. In the view of the US 
Panel, societal costs include time costs of patients, and maybe future health and non-health consumption 
but not productivity changes. This distinction has been contested by a number of authors51;53;158, as 
described earlier; also the Danish and Swedish recommendations for cost-effectiveness analysis deviate 
from the US Panel recommendations on this issue64;65. In addition, the review in chapter IV demonstrated 
that the societal perspective was interpreted rather differently in the few studies that actually applied such 
a perspective. Paper 4 focuses on the implications of including all future costs in the cost-effectiveness 
analysis; that is, applying a societal perspective including productivity and consumption changes in the 
future. 
 
Data sources 
Above, it was described how economic evaluations can be based on RCT-data, register-based data, or 
extrapolated data from RCTs and registers. It has been argued that the choice of data should be based on 
considerations on efficacy versus applicability and not only adherence to a hierarchy. Paper 3 provides an 
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example of a register based economic evaluation while the other three papers are not economic 
evaluations per se. The analyses in all four papers are register-based. 
 
The data source used in papers 1 and 2 is a cohort consisting of health interview survey data merged with 
register data89. The first survey was carried out in 1987 and the latest in 2005. For all respondents, a vast 
amount of register data on use of health care services, labour market behaviour, income, socio-economic 
and demographic parameters has been retrieved. In addition, the surveys include nationally representative 
information on HRQoL, lifestyle, self-reported health and use of health services etc. The cohort, consisting 
of these two data sources and covering a long period of time, thus provides a powerful source of data for 
use in economic evaluation.  
 
As such a cohort enables for adjustment for a variety of covariates and includes a total of more than 30,000 
individuals, it should not be considered inferior to RCTs as a tool for economic evaluation. Paper 1 used 
regression models with adjustment for a number of covariates to isolate the health care cost of heart 
disease and risk behaviour. Paper 2 used individual matching, where CHD-patients were matched with up 
to five individuals without CHD by means of various socio-economic and demographic characteristics. Using 
available covariates for confounder control does not prevent other factors from confounding results 
because the possibility of a confounder not taken into account will always exist, at least in theory. However 
all covariates that realistically could impact on results have been taken into account in the studies based on 
the DANCOS cohort13;16. 
 
Paper 3 was based on a clinical database, thus it was also a register based analysis. Here as well, a number 
of covariates, clinical as well as demographic have been adjusted for. The economic evaluation in paper 3 is 
aimed at being applicable in the real world, as the data derived from everyday clinical practice. The study 
covered a field of vast RCT evidence, however there is no convincing evidence to support the use of drug-
eluting stents in the literature159. The use of real life data in combination with the longer time frame in 
paper 3 provided a different perspective on the cost-effectiveness of drug-eluting stents.  
 
Paper 4 used register information for the entire Danish population on income, production, health care, etc. 
It was not an economic evaluation but intended to provide data for use in economic evaluations. The 
analysis focused on 2005 data and thus provided a cross-sectional picture of production and consumption 
in the Danish population.  
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In the following chapters, the findings and key issues of the four papers are briefly introduced, before 
concluding on the main themes of this thesis. 
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VI.  Costs of heart disease and risk behaviour 
(paper 1) 
 
 
In this study, the attributable health care costs of heart disease were established. Furthermore, we 
analysed the additional health care costs for heart patients with risk behaviour before their first heart 
disease-related hospital admission.  
 
The study was based on the notion that cost-of-illness estimates per se provide little guidance for decision 
making when applied outside the context of economic evaluations. However, economic evaluation of 
prevention programmes specifically targeted towards patients with heart disease may need cost figures of 
health care costs for patients with and without a history of heart disease. This study aimed therefore to 
inform decision-making about the cost consequences of risk behaviour amongst future heart patients.  
 
The data for the study was derived from a cohort consisting of participants in a national representative 
health interview survey combined with comprehensive register based information89. The register-based 
information about hospital diagnosis was used to identify patients with heart disease. We compared health 
care consumption amongst individuals who developed heart disease during 2002-2005 with health care 
consumption for individuals free of heart disease. We established the overall health care costs attributable 
to heart disease by use of linear regression with adjustment for confounding factors.  
 
In addition, we estimated the attributable costs of excess drinking, physical inactivity and smoking amongst 
individuals that would become heart patients. Again, we adjusted for confounding factors and estimated 
attributable costs in a linear regression.  
 
In the overall assessment of attributable costs, we found that individuals with heart disease on average cost 
the health care system €3,195 per person-year more than individuals without heart disease. This figure was 
statistically significant and presents a rationale for prevention of heart disease. Further, it reflects that 
heart disease is rather costly to the health care sector but also that other diseases related to the heart 
disease incur additional costs.  
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Amongst heart patients, individuals with a history of an unhealthy lifestyle incur higher health care costs 
than heart patients without a history of risk behaviour. The attributable cost of unhealthy lifestyle factors 
amongst individuals at risk of heart disease was 11-16 percent of the attributable cost of heart disease. 
 
Heart patients with a history of excess drinking had health care costs of €503 more per person-year than 
heart patients without such history. For heart patients who previously smoked, the health care costs were 
€474 more per person-year than for never-smokers amongst heart patients. Physical inactivity in the past 
rendered a difference of €362 in health care costs per person-year. All figures were statistically significant.  
 
The study provides a strong rationale for prevention of heart disease as well as risk behaviour, as it shows 
that heart disease incurs statistically significant additional costs to the health care sector, and more so if 
heart patients have a history of unhealthy lifestyle. Consequently, strategies to prevent or cease unhealthy 
lifestyle may not only result in cost savings due to avoided heart disease. Additional cost savings may be 
obtained because heart patients who prior to the disease led a more healthy life consume fewer health 
care resources. 
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VII.  Short and long-term labour market 
consequences of coronary heart disease (paper 
2) 
 
 
This study focused on the labour market behaviour of individuals that have experienced CHD. Amongst 
survivors of CHD, some choose to leave the labour market as an immediate result of their disease. Most 
studies of labour market withdrawal however fail to take into account that CHD often occurs at an age 
where most individuals consider retirement anyway5-8;160-162. It is therefore necessary to compare the 
labour market behaviour of CHD patients with a comparable reference group.  
 
Also, the time frame of the analysis of labour market behaviour is often a year or less, however this does 
not take into account that some heart patients may return to work following their admission and 
subsequently retire earlier than they would have done had they not been ill.  
 
This study, therefore, analysed to what extent individuals with coronary heart disease leave the labour 
market earlier than individuals without coronary heart disease in the short-term as well as in the long-term, 
and discussed the implications for rehabilitation. 
 
We identified heart patients from the merger of health interview survey data and register data in the 
Danish National Cohort study89 and followed them from the year of their first hospital admission for 
coronary heart disease and onwards for up to 23 years. Individuals with coronary heart disease were 
individually matched with individuals without coronary heart disease. We analysed their short-term labour 
market participation and compared the long-term risk of labour market withdrawal for the two groups by 
means of Cox regression. 
 
In the short-term, that is, the first year after the first coronary heart disease-related admission, 79 percent 
of heart patients maintained their labour market participation compared with 93 percent of individuals 
without coronary heart disease. In the long-term, heart patients had a hazard ratio of 1.32 for withdrawal 
compared with their matched counterparts, which was statistically significant. This means that heart 
patients were on the labour market, on average, for 0.8 years less than the individuals without coronary 
heart disease. Stratified analyses showed that, in particular, heart patients aged less than 60 years and 
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individuals employed as manual labour may benefit from cardiac rehabilitation, as rehabilitation aims to 
maintain and extend labour market participation10. 
 
The study showed that there remains a potential for cardiac rehabilitation to return heart patients to work 
and to maintain their employment status until they would otherwise have retired. In addition, greater focus 
in cardiac rehabilitation on returning individuals aged less than 60 in particular, and manual workers to the 
labour market might be worthwhile.
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VIII.  Painting the full picture: the case of long-
term cost-effectiveness of drug-eluting stents 
(paper 3) 
 
 
This study provides a case for the use of register-based data in economic evaluation and for taking into 
account the long-term costs and effects of a heath care intervention. The topic of drug eluting stents has 
been thoroughly assessed in a variety of randomised controlled trials and thus studies with a high degree of 
internal validity9;163. The longer term perspective has not been fully assessed yet despite the product being 
on the market for about 6 years.  
Coronary angioplasty is a treatment of CHD in which a catheter widens a coronary artery which is blocked, 
by means of a balloon and leaves a stent in the artery in order to prevent it from blocking again. Paper 3 
focuses on drug-eluting stents in coronary angioplasty. Drug-eluting stents were introduced about 2003 as 
an alternative to bare metal stents. 
The bulk of literature in this field focus on short-term effects163 while the cost-effectiveness on the longer 
term seems to be rather unexplored. However, as the longer term costs and effects are highly relevant, for 
clinical practice as well as for decision making, we analysed the cost-effectiveness of drug-eluting stents in 
coronary angioplasty compared to bare metal stents over a five year period. 
For this study, we obtained cost and effect measures from a database with observational data on patients 
receiving non-acute bare metal stents or drug-eluting stents. The data was joined with information from a 
patient survey on health related quality of life, and administrative data from the hospital. Taking into 
consideration that patient groups in an observational study may be less comparable than in a RCT, we 
adjusted for possible confounders in the analysis.  
We identified differences in the outcomes of interest: repeat revascularisations and mortality by means of 
duration analysis. As the assumption of proportional hazards was violated, thus rendering Cox regression 
inappropriate, we used a Weibull accelerated failure time regression model for this analysis. 
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While QALYs were used as the effect measure in the CEA, the development of repeat revascularisations 
impacted on costs, and was analysed separately.  
We used a Markov model to simulate the incremental cost-effectiveness using different time horizons. The 
incremental cost-effectiveness of drug-eluting stents over bare metal stents was €14,000 (CI –18,500 – 
46,500) per QALY gained over five years. After one year, the time frame of many randomised studies, the 
incremental cost-effectiveness of drug-eluting stents, that is, the cost of achieving one additional QALY was 
prohibitively high. 
In addition, the development in repeat revascularisations was different between the two types of stents 
over the five-year period, also pointing to the importance of a long analysis time frame. 
Thus, the study provided an illustrative example of the profound impact of the analysis time frame. The two 
stent types displayed differing developments of effects over the five year period, adding to the argument of 
the sufficient time frame. Thus, while results after five years remained inconclusive on the recommended 
stent type, the expanded time horizon rendered important differences in the main finding. 
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IX.  Future costs in cost-effectiveness analysis 
(Paper 4) 
 
 
The topic of future costs in economic evaluations of health care interventions has been debated for almost 
two decades53;56;164. Amongst the topics that have been discussed are application and definition of the 
societal perspective, notably the human capital approach versus the friction cost approach; whether 
productivity changes are captured by the QALY, and therefore should be excluded; and whether future 
unrelated health care costs should be included or not. Most recently, the debate has focused on changes in 
future consumption, and to a lesser degree production, following an increase in life expectancy49-51;165.  
 
Costs in cost-effectiveness analysis always include the so-called direct costs, costs directly related to the 
intervention; as well as downstream health care costs, at least within the study period. Most studies also 
include unrelated health care costs within the study period. The controversy pertains to the income effects 
of the increased life expectancy following from the intervention, consumption and production changes.  
 
This study concentrated on the three components of future costs, or survivor costs: changes in health care 
consumption, changes in non-health care consumption, and changes in productivity following a health care 
intervention that increases the length of life of its participants. We introduced the term ‘net incremental 
consumption’ relating to changes in consumption (health care and non-health care) minus changes in 
productivity. 
 
The aim of this study was to assess the magnitude of net incremental consumption in the Danish 
population using register-based data for one-year age groups; and to analyse the impact on the cost-
effectiveness ratio of including net incremental consumption in the computation. 
 
We used register-based data for the entire Danish population aged 16 and above in 2005. We defined 
production as gross earnings and subtracted any income from social security. Consumption was divided 
into health care consumption and non-health care consumption. We defined health care consumption as 
the share of health care paid for by the public authorities, including hospital treatment, treatment by 
general practitioners and practicing specialists, and the share of prescribed pharmaceuticals paid for by the 
authorities.  
Short and long-term consequences of coronary heart disease 
 
 
 
Page 70 
 
 
To assess the magnitude of non-health care consumption, it was necessary to make a number of 
assumptions, as individual consumption cannot be retrieved from registers. We assumed savings to be 
constant during productive ages, and consumption of public services other than health care to equal tariffs. 
Further, we assumed that individual consumption was evenly distributed within households. Consumption 
was then equal to disposable income, minus savings (during productive ages), plus an age-specific assumed 
consumption of public goods. This figure was summed for each household and divided by number of 
members in the household to obtain a measure of children’s consumption. 
 
We calculated lifetime figures per age group, adjusted these for survival and discounted using a discount 
rate of 3 percent p.a., to obtain the net present value of net consumption in each age group. In addition, 
we computed costs per life year for application in a cost-effectiveness analysis.  
 
The analysis showed that net consumption is positive (that is, consumption exceeds production) before age 
20 and after age 65. Between age 20 and 65, production exceeds consumption and individuals in these age 
groups can be considered net contributors. The expected net consumption per added life year in a 30 year 
old person is more than €-9,000, while the same figure in a 70-year old is €10,300 per added life year, equal 
to a difference of about €19,500 when these figures are included in the cost-effectiveness measurement. 
 
As an example of the impact of including these figures in the cost-effectiveness analysis, consider the 
example of a bypass surgery in a 65 year old person. The surgery has a (hypothetical) incremental cost-
effectiveness ratio of €15,000 per life year gained, compared to medical management. Inclusion of net 
incremental consumption would produce an ICER of €23,700 per life year gained, whereas the same 
intervention in a 40 year old has an ICER of €9,500, when net incremental consumption is included.  
 
The results of the analysis point to the vast significance of age. The aim of economic evaluation of health 
care interventions is to aid decision makers in their prioritisation of interventions. Interventions aimed at 
younger patients will appear more cost-effective relative to interventions aimed at older patients, when 
future costs are included in the computation.  
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X.  Conclusion  
 
 
The high prevalence and important impact of CHD, as well as the presence of a wide range of interventions 
aiming to treat or prevent CHD make the rationale for analysing short as well as long-term resource 
consequences of the condition quite obvious.  
 
This thesis has assessed and discussed the time frame, data sources and perspectives for analysing long-
term costs and effects of interventions in the field of preventing and treating coronary heart disease. In the 
four papers, important resource consequences have been identified. 
 
The rationale 
The costs and consequences of CHD occur at multiple levels and at different points in time. I have argued 
that a comprehensive assessment of costs and other consequences of CHD should include the long term, 
which impacts other sectors than the health care sector. I have argued in favour of using the best available 
data for economic evaluations, and these may not be trial-based. Instead, use of register-based data is a 
feasible choice for economic evaluation and assessment of consequences of disease, because they provide 
a longer time frame than trials and their information on costs and effects resemble a real-world situation 
more closely. In addition, large registers and cohorts supply a larger data base than most trials, as well as 
information on a wide range of parameters so that results can be adjusted for possible confounders. 
 
Findings 
I have identified a number of advantages of using register-based data in economic evaluation. Compared to 
RCTs, the external validity, i.e. the applicability in clinical settings, is better in register-data. In addition, 
there are good opportunities for retrospective analyses of costs and effects over long time periods in 
register data. 
 
In areas where RCTs appear difficult to conduct, there is a specific rationale for register-based analysis. 
Prevention of heart disease – or other diseases – is one such area. Generally, registers are as applicable for 
use in economic evaluations as RCTs, regardless of whether these registers are used alone or in 
combination with survey data. It should not be the conduction of the data collection that determines 
whether a data source should be used in favour of another; rather, the data source ought to be selected on 
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the basis of considerations regarding the number of individuals, the applicability for clinical practice and 
perhaps most importantly, the time frame of data. 
 
In paper 1, we found that the health care costs attributable to CHD were significant and increased when 
individuals with heart disease had a history of an unhealthy lifestyle. 
 
Paper 3 provided incremental cost-effectiveness ratios for a very widespread treatment strategy (drug-
eluting stents), and demonstrated that an extended analysis time frame altered results significantly. 
 
In paper 2, we found that CHD patients leave the labour market earlier than a comparable reference group, 
taking into account that CHD occurs at an age where many individuals consider withdrawing from the 
labour market anyway. The earlier labour market withdrawal points to the importance of the societal 
impact of CHD. 
 
Figures for the societal impact of disease are often not readily available. In Sweden, average age group 
specific figures for survivor costs have been estimated with a view to application in economic 
evaluations166. In paper 4, similar figures have been computed for Denmark, based on information at 
individual level on consumption and production in one-year age groups. 
 
The analyses 
I have demonstrated the feasibility of register-based data as well as the importance of a long time frame by 
using register-based data for assessing the short and long-term consequences of CHD through the four 
papers in this PhD. Papers 1 and 2 are based on a cohort comprised of respondents to the NHIS, which 
comprises survey information as well as comprehensive register information over a long time period. 
Papers 3 and 4 are register-based as well. 
 
Paper 1 demonstrated that using incidence-based figures and the attributable cost approach provides an 
identification of health care costs that could have been avoided if CHD was prevented, or if individuals at 
risk of CHD had adopted a healthier life style. 
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In paper 2, adoption of a long time frame showed that there are long-term labour market consequences of 
CHD in addition to the short-term effect. Also, the register-based analysis provided the option of isolating 
the effect of CHD in labour market withdrawal, thus excluding the impact of age. 
 
Paper 3 provides an example of an economic evaluation with a longer time frame than most studies in the 
field. Indeed, the findings changed markedly during the study period, thus making a case for the longer 
time horizon. 
 
The results generated in paper 4 could not have been calculated by other feasible means than a register-
based analysis. While adopting a cross-sectional view, the results of the analysis are presented with a view 
to application in evaluations with a long time horizon. 
 
Challenges 
Clearly, use of register-based data entails a number of challenges. Firstly, internal validity problems and 
possible confounders should be accounted for. Secondly, administrative registers do not include 
information on self-assessed health, lifestyle, or other self-reported parameters. Cohorts normally include 
these data; however as some cohort participants may not respond, the analysis could suffer from selection 
bias, as is the case for trial-based analyses as well. Therefore, whenever the analysis involves response or 
consent from participants, selection bias should be accounted for. 
 
In Denmark, administrative registers have been widely used for several years. The data are used by 
researchers as well, in particular for health services research. Most registers are comprehensive as they 
cover the entire population, and of good quality since they have been validated and developed for several 
years. Thus, the health care registers include several variables over long periods of time, enabling 
researchers to use them for cross-sectional as well as time series analyses.  
 
Administrative registers were not designed for research purposes per se. The main implication of this is that 
the quality of data may be too poor to base research conclusions on. The Danish health care registers have 
for several years not only been used for administrative purposes but also for remuneration of health care 
professionals. Therefore there has been a motivation for the professionals to enter correct and timely data 
into the registers. However, the limitations of the administrative data are important and should be taken 
into account. 
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Perspectives 
It is important to apply a long time frame in future analyses of health care or health promotion 
interventions. This argument has been made with specific reference to CHD, although it applies to other 
diseases as well, in particular chronic conditions and lifestyle-related diseases. In addition, the societal 
perspective should be applied, if possible, as variations in life expectancy and HRQoL following a health 
care or health promotion intervention impact on future consumption and production which in turn has a 
societal effect beyond the individual concerned. 
 
Therefore, the potential of using register-based data in economic evaluations, taking into account the 
caveats of such data, can still be expanded. 
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